TRUPANION, INC., 10-K filed on 2/27/2025
Annual Report
v3.25.0.1
Cover Page Document - USD ($)
 12 Months Ended
Dec. 31, 2024
Feb. 19, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Document Transition Report false    
Entity File Number 001-36537    
Entity Registrant Name TRUPANION, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 83-0480694    
Entity Address, Address Line One 6100 4th Avenue S, Suite 200    
Entity Address, City or Town Seattle,    
Entity Address, State or Province WA    
Entity Address, Postal Zip Code 98108    
City Area Code (855)    
Local Phone Number 727 - 9079    
Title of 12(b) Security Common stock, $0.00001 par value per share    
Trading Symbol TRUP    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 978,851,803
Entity Common Stock, Shares Outstanding   42,490,664  
Entity Central Index Key 0001371285    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag false    
Document Financial Statement Error Correction [Flag] false    
v3.25.0.1
Audit Information
 12 Months Ended
Dec. 31, 2024
Audit Information [Abstract]  
Auditor Firm ID 42
Auditor Name Ernst & Young LLP
Auditor Location Seattle, Washington
v3.25.0.1
Consolidated Statement of Operations - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Revenue $ 1,285,684,000 $ 1,108,605,000 $ 905,179,000
Veterinary invoice expense 949,148,000 831,055,000 649,737,000
Other cost of revenue 157,738,000 146,534,000 133,257,000
Total cost of revenue 1,106,886,000 977,589,000 782,994,000
Technology and development 31,255,000 21,403,000 25,133,000
General and administrative 63,731,000 60,207,000 39,379,000
New pet acquisition expense 71,379,000 77,372,000 89,500,000
Goodwill, Impairment Loss 5,299,000 0 0
Depreciation and amortization 16,466,000 12,474,000 10,921,000
Total operating expenses 188,130,000 171,456,000 164,933,000
Gain (loss) from investment in joint venture (182,000) (219,000) (253,000)
Operating loss (9,514,000) (40,659,000) (43,001,000)
Interest expense 14,498,000 12,077,000 4,267,000
Other expense (income), net (14,374,000) (7,701,000) (3,072,000)
Loss before income taxes (9,638,000) (45,035,000) (44,196,000)
Income tax expense (benefit) (5,000) (342,000) 476,000
Net loss $ (9,633,000) $ (44,693,000) $ (44,672,000)
Earnings Per Share, Basic $ (0.23) $ (1.08) $ (1.10)
Earnings Per Share, Diluted $ (0.23) $ (1.08) $ (1.10)
Weighted Average Number of Shares Outstanding, Basic 42,158,773 41,436,882 40,765,355
Weighted Average Number of Shares Outstanding, Diluted 42,158,773 41,436,882 40,765,355
v3.25.0.1
Consolidated Statement of Comprehensive Income Statement - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Net loss $ (9,633) $ (44,693) $ (44,672)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax (3,037) 2,712 (4,412)
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 22 3,992 (4,966)
Other Comprehensive Income (Loss), Net of Tax, Total (3,015) 6,704 (9,378)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total $ (12,648) $ (37,989) $ (54,050)
v3.25.0.1
Consolidated Balance Sheet - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Assets [Abstract]    
Cash and cash equivalents $ 160,295,000 $ 147,501,000
Short-term investments 147,089,000 129,667,000
Accounts and other receivables 274,031,000 267,899,000
Prepaid expenses and other assets 15,912,000 17,022,000
Total current assets 597,327,000 562,089,000
Restricted cash 39,235,000 22,963,000
Long-term investments 373,000 12,866,000
Property, equipment, and internal-use software, net 102,191,000 103,650,000
Intangible assets, net 13,177,000 18,745,000
Other long-term assets 17,579,000 18,922,000
Goodwill 36,971,000 43,713,000
Total assets 806,853,000 782,948,000
Liabilities and Equity [Abstract]    
Accounts payable 11,532,000 10,505,000
Accrued liabilities and other current liabilities 33,469,000 34,052,000
Reserve for veterinary invoices 51,635,000 63,238,000
Deferred revenue 251,640,000 235,329,000
Long-Term Debt, Current Maturities 1,350,000 1,350,000
Total current liabilities 349,626,000 344,474,000
Long-Term Debt 127,537,000 127,580,000
Deferred tax liabilities 1,946,000 2,685,000
Other liabilities 4,476,000 4,487,000
Total liabilities 483,585,000 479,226,000
Common stock: $0.00001 par value per share 0 0
Preferred stock: $0.00001 par value per share 0 0
Additional paid-in capital 568,302,000 536,108,000
Accumulated other comprehensive income (loss) (2,612,000) 403,000
Accumulated deficit (225,888,000) (216,255,000)
Treasury stock, at cost (16,534,000) (16,534,000)
Total stockholders' equity 323,268,000 303,722,000
Total liabilities and stockholders’ equity $ 806,853,000 $ 782,948,000
Common Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001
Common Stock, Shares Authorized 100,000,000 100,000,000
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Authorized 10,000,000 10,000,000
Preferred Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001
v3.25.0.1
Consolidated Balance Sheet Condensed Consolidated Balance Sheet Parentheticals - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Common Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001
Common Stock, Shares Authorized 100,000,000 100,000,000
Common Stock, Shares, Issued 43,516,631 42,887,052
Common Stock, Shares, Outstanding 42,488,445 41,858,866
Preferred Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001
Preferred Stock, Shares Authorized 10,000,000 10,000,000
Preferred Stock, Shares Issued 0 0
Treasury Stock, Common, Shares 1,028,186 1,028,186
Allowance for Doubtful Accounts, Premiums and Other Receivables $ 1,117,000 $ 1,085,000
v3.25.0.1
Consolidated Statement of Stockholders' Equity - USD ($)
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Treasury Stock, Common [Member]
Beginning balance (in shares) at Dec. 31, 2021   40,475,185        
Beginning balance at Dec. 31, 2021 $ 332,200,000 $ 0 $ 466,792,000 $ (126,890,000) $ 3,077,000 $ (10,779,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock in connection with the Company's equity award programs, net of tax withholdings (in shares)   632,994        
Issuance of common stock in connection with the Company's equity award programs, net of tax withholdings (2,124,000)   (2,124,000)      
Stock-based compensation expense 35,026,000   35,026,000      
Repurchase of common stock (in shares)   (95,021)        
Treasury Stock, Value, Acquired, Cost Method (5,755,000)         5,755,000
Other comprehensive income (loss) (9,378,000)       (9,378,000)  
Net loss (44,672,000)     (44,672,000)    
Ending balance (in shares) at Dec. 31, 2022   41,013,158        
Ending balance at Dec. 31, 2022 305,297,000 $ 0 499,694,000 (171,562,000) (6,301,000) (16,534,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock in connection with the Company's equity award programs, net of tax withholdings (in shares)   845,708        
Issuance of common stock in connection with the Company's equity award programs, net of tax withholdings (1,118,000)   (1,118,000)      
Stock-based compensation expense 35,296,000   35,296,000      
Treasury Stock, Value, Acquired, Cost Method 0          
Other comprehensive income (loss) 6,704,000       6,704,000  
Net loss $ (44,693,000)     (44,693,000)    
Ending balance (in shares) at Dec. 31, 2023 41,858,866 41,858,866        
Ending balance at Dec. 31, 2023 $ 303,722,000 $ 0 536,108,000 (216,255,000) 403,000 (16,534,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock in connection with the Company's equity award programs, net of tax withholdings (in shares)   629,579        
Issuance of common stock in connection with the Company's equity award programs, net of tax withholdings (1,743,000)   (1,743,000)      
Stock-based compensation expense $ 33,937,000   33,937,000      
Repurchase of common stock (in shares) 0          
Other comprehensive income (loss) $ (3,015,000)       (3,015,000)  
Net loss $ (9,633,000)     (9,633,000)    
Ending balance (in shares) at Dec. 31, 2024 42,488,445 42,488,445        
Ending balance at Dec. 31, 2024 $ 323,268,000 $ 0 $ 568,302,000 $ (225,888,000) $ (2,612,000) $ (16,534,000)
v3.25.0.1
Consolidated Statement of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Net Cash Provided by (Used in) Operating Activities [Abstract]      
Net loss $ (9,633,000) $ (44,693,000) $ (44,672,000)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]      
Depreciation and amortization 16,466,000 12,474,000 10,921,000
Stock-based compensation expense 33,432,000 33,161,000 33,393,000
Goodwill, Impairment Loss 5,299,000 0 0
Other, net (1,748,000) 1,347,000 1,051,000
Increase (Decrease) in Operating Assets [Abstract]      
Accounts and other receivables (6,717,000) (35,440,000) (66,982,000)
Prepaid expenses and other assets 3,215,000 (1,907,000) (5,227,000)
Accounts payable, accrued liabilities, and other liabilities 2,084,000 1,644,000 3,136,000
Reserve for veterinary invoices (11,310,000) 19,485,000 4,227,000
Deferred revenue 17,199,000 32,567,000 56,153,000
Net cash provided by (used in) operating activities 48,287,000 18,638,000 (8,000,000)
Net Cash Provided by (Used in) Investing Activities [Abstract]      
Purchases of investment securities (133,493,000) (165,936,000) (273,006,000)
Maturities and sales of investment securities 127,653,000 190,270,000 239,210,000
Cash paid in business acquisition, net of cash acquired 0 0 (15,034,000)
Purchases of property, equipment, and internal-use software (9,716,000) (18,280,000) (17,088,000)
Other 2,099,000 1,585,000 (1,598,000)
Net cash provided by (used in) investing activities (13,457,000) 7,639,000 (67,516,000)
Net Cash Provided by (Used in) Financing Activities [Abstract]      
Payments for Repurchase of Common Stock 0 0 (5,755,000)
Proceeds from exercise of stock options 752,000 2,655,000 2,290,000
Shares withheld to satisfy tax withholding (2,519,000) (1,536,000) (4,359,000)
Proceeds from debt financing, net of financing fees 0 60,102,000 69,138,000
Repayment of debt financing (1,350,000) (1,717,000) (571,000)
Other (840,000) (378,000) 0
Net cash provided by (used in) financing activities (3,957,000) 59,126,000 60,743,000
Net change in cash, cash equivalents, and restricted cash 28,996,000 85,827,000 (16,232,000)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations (1,877,000) 424,000 (1,459,000)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance 170,464,000 84,637,000 100,869,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance 199,530,000 170,464,000 84,637,000
Supplemental Cash Flow Information [Abstract]      
Income taxes paid (546,000) (611,000) (2,498,000)
Interest paid 13,191,000 12,100,000 3,353,000
Purchases of property, equipment, and internal-use software included in accounts payable and accrued liabilities $ 534,000 $ 887,000 $ 1,324,000
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies (Notes)
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations and Summary of Significant Accounting Policies Nature of Operations and Summary of Significant Accounting Policies
Description of Business
Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the "Company") provides medical insurance for cats and dogs in the United States, Canada, certain countries in Continental Europe, and Australia. Through our data-driven, vertically-integrated approach, we develop and offer high value medical insurance products, priced specifically for each pet’s unique characteristics and coverage level.
Basis of Presentation
The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At times, cash on deposit may be in excess of the applicable federal deposit insurance corporation limits.
The Company considers any cash account not held in trust for a third party that is contractually restricted to withdrawal or use to be restricted cash. The Company is required to maintain certain restricted cash balances to comply with insurance company regulations. As of December 31, 2024, the Company was in compliance with all requirements.
Accounts and Other Receivables
Accounts and other receivables are comprised of trade receivables and other miscellaneous receivables and are carried at their estimated collectible amounts. Trade receivables are primarily related to the Company’s other business segment where the Company generates revenue from underwriting policies through unaffiliated general agents. These policies are typically annual policies, with monthly payment terms through the end of the twelve-month period. The Company had $252.0 million and $249.8 million accounts receivable associated with underwriting these policies as of December 31, 2024 and 2023, respectively. During the year ended December 31, 2023, the Company incurred a non-recurring $3.8 million settlement of accounts receivable due to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers.
Deferred Acquisition Costs
The Company incurs certain costs, including premium taxes, enrollment-based bonuses, and referral fees that directly relate to the successful acquisition of new or renewal customer contracts. These costs are deferred and are included in prepaid expenses and other assets on the consolidated balance sheet and amortized over the related policy term to the applicable financial statement line item, either new pet acquisition expense or other cost of revenue. Deferred acquisition costs as of December 31, 2024 and 2023 were $7.5 million and $7.4 million, respectively. Amortized deferred acquisition costs classified within new pet acquisition expense amounted to $6.9 million, $6.0 million, and $4.9 million and amortized deferred acquisition costs classified within other cost of revenue amounted to $51.5 million, $45.6 million, and $33.9 million, for the years ended December 31, 2024, 2023, and 2022, respectively.
Investments
The Company invests in investment grade fixed maturity securities of varying maturities. Available-for-sale securities are reported at fair value with unrealized gains and losses included in accumulated other comprehensive income (loss). Held-to-maturity securities are reported at amortized cost. Premiums or discounts on fixed maturity securities are amortized or accreted over the life of the security and included in interest income. There were $0.4 million in realized gains and $0.3 million in realized losses on sales of fixed maturity securities during the year ended December 31, 2024, $0.3 million in realized gains and $0.9 million in realized losses on sales of fixed maturity securities during the year ended December 31, 2023, and no realized gains or losses on sales of fixed maturity securities during the years ended December 31, 2022.
Each reporting period, the Company evaluates whether declines in fair value of its investments below carrying value are the result of expected credit losses. This evaluation includes the Company's ability and intent to hold these investments until recovery of carrying value occurs, including an evaluation of all available information relevant to the collectability of the security, including past events, current conditions, and reasonable and supportable forecasts. Expected credit losses are recorded as an allowance through other expense (income), net on the Company's consolidated statements of operations.
Fair Value of Financial Instruments
The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:
Level 1 - Quoted prices in active markets for identical assets or liabilities
Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly
Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability
The Company's financial instruments, in addition to those presented in Note 7, Fair Value, include cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities. The carrying amounts of accounts receivable, accounts payable, and accrued liabilities approximate fair value because of the short-term nature of these instruments.
Property, Equipment, and Internal-Use Software
Property, equipment, and internal-use software primarily consists of building, land and land improvements, office equipment, internal-use software related to the Company’s website, and internal support systems. Internal-use software is capitalized during the application development stage of the project. Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of the respective asset:
LandNot depreciable
Land improvements10years
Building39years
Software3to5years
Office equipment3to5years
Goodwill and Intangible Assets
Goodwill and indefinite-lived intangible assets are not amortized. The Company reviews these assets for impairment at least annually or if indicators of potential impairment exist. Acquired finite-lived intangibles are amortized on a straight-line basis over the estimated useful lives of the assets. The Company recognized impairment charges on goodwill totaling $5.2 million during the year ended December 31, 2024, and no goodwill impairment charges in the years ended December 31, 2023 and 2022. The Company recognized no impairment on indefinite-lived intangible assets during the years ended December 31, 2024, 2023, and 2022. See Note 4 to these financial statements for further details on goodwill and related impairment charges.
Asset Impairment
Long-lived assets, including property, equipment, internal-use software, and finite-lived intangible assets, are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Should an impairment exist, the impairment loss would be measured as the amount the asset's carrying value exceeds its fair value. The Company has recognized no impairment loss on long-lived assets, including property, equipment, internal-use software, and finite-lived intangible assets for the years ended December 31, 2024, 2023, and 2022.
Reserve for Veterinary Invoices
Reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary claims that have been incurred but not yet paid as of the reporting date. The reserve also includes the Company's estimate of related internal processing costs. To determine the accrual, the Company makes assumptions based on its historical experience, including the number of veterinary invoices it expects to receive, the average cost of those veterinary invoices, the length of time between the date of the veterinary invoice and the date the Company receives it, the member's chosen deductible, and the Company's expected cost to process and administer the payments. As of each balance sheet date, the Company reevaluates its reserve and adjusts the estimate for new information.
Deferred Revenue
Deferred revenue is primarily related to the Company’s other business segment where the Company generates revenue from underwriting policies through unaffiliated general agents. These policies are typically annual policies for which revenue is recognized pro-rata over the twelve-month policy period. Deferred revenue also consists of subscription payments received or billed in advance of the subscription services within the Company's subscription business.
Revenue Recognition
Revenue is recognized pro-rata over the term of the customer contracts. The Company generates revenue primarily from subscription payments and through underwriting policies for unaffiliated general agents. For the year ended December 31, 2024, premiums from policies sourced by general agents accounted for 32% of our total revenue, and one general agent sourced members whose premiums accounted for over 10% of our total revenue.
Veterinary Invoice Expense
Veterinary invoice expense includes the Company’s costs to review and pay veterinary invoices, administer the payments, and provide member services, and other operating expenses directly or indirectly related to this process. The Company also accrues for veterinary claims that have been incurred but not yet paid and the estimated cost of processing these invoices. Veterinary invoice expense also includes amounts paid by unaffiliated general agents on our behalf, and an estimate of amounts incurred and not yet paid for the other business segment.
Other Cost of Revenue
Other cost of revenue for the subscription business segment includes direct and indirect member service expenses, Territory Partner renewal fees, credit card transaction fees and premium tax expenses. Other cost of revenue for the other business segment includes the commissions the Company pays to unaffiliated general agents and costs to administer the programs in the other business segment.
Technology and Development
Technology and development expenses primarily consist of personnel costs and related expenses for the Company's technology staff, which includes information technology development and infrastructure support and third-party services. It also includes expenses associated with development of new products and offerings.
General and Administrative
General and administrative expenses consist primarily of personnel costs and related expenses for the Company’s finance, actuarial, human resources, legal, regulatory, and general management functions, as well as facilities and professional services.
New Pet Acquisition Expense
New pet acquisition expense primarily consists of costs, including employee compensation, to educate veterinarians and consumers about the benefits of Trupanion, to generate leads and to convert leads into enrolled pets, as well as print, online and promotional advertising costs.
Other Expense (Income), Net
Other income, net, totaled $14.4 million, $7.7 million, and $3.1 million, including interest income of $12.4 million, $9.0 million, and $3.0 million for the years ended December 31, 2024, 2023, and 2022. In 2023 other income was offset by a credit loss of $1.7 million related to the Company's preferred stock investment (refer to Note 6, Other Investments). This loss was subsequently determined to be recovered, and reversed through other income, during the year ended December 31, 2024.
Advertising
Advertising costs are expensed as incurred. Advertising costs amounted to $13.3 million, $16.9 million and $25.5 million, in the years ended December 31, 2024, 2023 and 2022, respectively.
Stock-Based Compensation
Compensation expense related to stock-based transactions, including employee and non-employee stock option awards, restricted stock awards, and restricted stock units, is measured and recognized in the financial statements based on fair value. The fair value of restricted stock awards and restricted stock units is the common stock price as of the measurement date.
Stock-based compensation expense for stock options and restricted stock units is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes forfeitures when they occur.
Income Taxes
The Company uses the asset and liability approach for accounting and reporting income taxes. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities, and their respective tax bases, operating loss, and tax credit carryforwards.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a tax rate change is recognized in the period that includes the enactment date. Valuation allowances are provided for when it is considered more likely than not that deferred tax assets will not be realized.
The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than a 50% likelihood of being realized. Penalties and interest are classified as a component of income taxes.
Foreign Currency Translation
The Company’s consolidated financial statements are reported in U.S. dollars. Assets and liabilities denominated in foreign currencies were translated to U.S. dollars, the reporting currency, at the exchange rates in effect on the balance sheet date. Revenue and expenses denominated in foreign currencies were translated to U.S. dollars using a weighted average rate for the relevant reporting period. Cumulative translation adjustments of $(3.1) million, $(0.1) million, and $(2.8) million were recorded in accumulated other comprehensive loss (income) as of December 31, 2024, 2023, and 2022, respectively.
Reclassifications
Certain presentation reclassifications have been made to prior-year deferred tax amounts disclosed within Note 16 of these financial statements to conform to current-year reporting classifications. These reclassifications had no impact on net earnings, total assets, total liabilities, total shareholders' equity, or cash flows.
Insurance Operations
Effective January 1, 2015, the Company formed a segregated account in Bermuda as part of Wyndham Insurance Company (SAC) Limited (WICL) and entered into a revised fronting and reinsurance arrangement with Accelerant Insurance Company of Canada, formerly known as Omega General Insurance Company, to include its newly formed segregated account. The Company maintains all risk with the business written in Canada and consolidates the entity in its financial statements. Dividends are allowed subject to the Segregated Accounts Company Act of 2000, which allows for dividends only to the extent that the entity remains solvent and the value of its assets remain greater than the aggregate of its liabilities and its issued share capital and share premium accounts.
For the Company’s Canadian business, all plans are written by Accelerant and the risk is assumed by the Company through a fronting and reinsurance agreement. Premiums are recognized and earned pro rata over the terms of the related customer contracts. Revenue recognized from the agreement in 2024, 2023, and 2022 was $206.7 million, $167.6 million and $135.9 million, respectively, and deferred revenue relating to this arrangement at December 31, 2024 and 2023 was $11.3 million and $9.5 million, respectively. Reinsurance revenue was 16%, 15%, and 15% of total revenue in 2024, 2023, and 2022, respectively. Cash designated for the purpose of paying claims related to this reinsurance agreement was $7.2 million and $11.2 million at December 31, 2024 and 2023, respectively. In addition, as required by the Office of the Superintendent of Financial Institutions regulations related to the Company’s reinsurance agreement with Accelerant, the Company is required to fund a Canadian Trust account with the greater of CAD $2.0 million or 120% of unearned Canadian premium plus 20% of outstanding Canadian claims, including all incurred but not reported claims. As of December 31, 2024, the account balance was CAD $19.9 million and the Company was in compliance with all requirements.

The Company has not transferred any risk to third-party reinsurers.
Concentrations of Credit Risk
Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents, investments, and debt. The Company manages its risk by investing cash equivalents and investment securities in money market instruments and securities of the U.S. government, U.S. government agencies and high-credit-quality issuers of debt securities.
v3.25.0.1
Net Loss per Share (Notes)
 12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Net Loss Per Share Net Loss per Share
Basic net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated using the weighted average number of shares of common stock plus, when dilutive, potential shares of common stock outstanding using the treasury-stock method. Potential shares of common stock outstanding include stock options, unvested restricted stock awards and restricted stock units.
The following potentially dilutive equity securities were not included in the diluted earnings per share of common stock calculation because they would have had an antidilutive effect:
 As of December 31,
 202420232022
Stock options347,334 408,970 629,650 
Restricted stock units970,739 714,382 1,112,552 
v3.25.0.1
Property Plant and Equipment (Notes)
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net Property, Equipment, and Internal-Use Software, Net
Property, equipment, and internal-use software, net consisted of the following (in thousands):
 December 31,
 20242023
Land and improvements$15,911 $15,911 
Building and improvements49,359 48,974 
Software64,368 40,097 
Office equipment and other6,123 6,129 
Construction in progress16,070 34,627 
Property, equipment and internal-use software, at cost151,831 145,738 
Less: Accumulated depreciation(49,640)(42,088)
Property and equipment, net$102,191 $103,650 
Depreciation expense related to property, equipment, and internal-use software was $11.2 million, $6.7 million and $6.1 million for the years ended December 31, 2024, 2023 and 2022, respectively.
v3.25.0.1
Intangible Assets (Notes)
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Goodwill and Intangible Assets
Goodwill arises from business acquisitions in which the purchase price exceeds the fair value of tangible and intangible assets acquired less assumed liabilities. The carrying values of goodwill and other intangible assets with indefinite lives are reviewed at least annually for possible impairment. The Company may first assess qualitative factors in order to determine if goodwill and indefinite-lived intangible assets are impaired. If through qualitative assessment it is determined that it is more likely than not that goodwill or indefinite-lived assets are not impaired, no further testing is required. If it is determined more likely than not that goodwill or indefinite-lived assets are impaired, the Company’s impairment testing continues with the estimation of reporting unit fair value using a combination of a market approach and an income (discounted cash flow) approach, at the reporting unit level. Estimates of fair value are based on the best information available to the Company as of the assessment date.
The Company has identified reporting units in conjunction with its annual goodwill impairment testing date during the fourth quarter of 2024. All of the Company’s goodwill has been assigned to three separate reporting units within our Subscription Business reportable segment: Trupanion Core – North America, Smart Paws, and PetExpert.
The following is a summary of goodwill by reportable segment for the years ended December 31, 2024 and 2023 (in thousands):
Subscription BusinessOther BusinessTotal
Balance as of January 1, 2023$41,983 $— $41,983 
Effects of foreign currency1,730 — 1,730 
Balance as of December 31, 202343,713 — 43,713 
Impairment charges(5,229)— (5,229)
Effects of foreign currency(1,513)— (1,513)
Balance as of December 31, 2024$36,971 $— $36,971 
In the fourth quarter of 2024, the Company performed its annual goodwill impairment test for all three reporting units with assigned goodwill and recognized impairment charges of $2.7 million and $2.5 million on the goodwill of Smart Paws and PetExpert, respectively, based on the fair value assessments performed after circumstances indicated that the goodwill of these reporting units more likely than not had become impaired. These circumstances primarily related to the Company’s decision to slow expansion efforts as the Company focuses capital allocation on reporting units operating within the Company's stated financial guardrails.
Following these impairment charges, no goodwill remains for Smart Paws and $6.7 million of goodwill remains for PetExpert, which could be further impaired in the future if this reporting unit fails to meet its revised financial projections.
The Company determined that the Trupanion Core – North America reporting unit was not at risk of goodwill impairment as of December 31, 2024 and 2023.
The following table presents the detail of intangible assets other than goodwill for the periods presented (in thousands):
Gross Carrying ValueAccumulated AmortizationNet Carrying ValueWeighted Average Remaining Useful Life as of December 31, 2024
December 31, 2024:
Licenses$4,773 $— $4,773 N/A
Trade name1,271 (531)740 5.8
Developed technologies16,835 (12,106)4,729 1.4
Customer relationships8,180 (6,394)1,786 1.2
Patents, trademarks, and other2,556 (1,407)1,149 3.0
Total Intangibles$33,615 $(20,438)$13,177 1.6
December 31, 2023:
Licenses$4,773 $— $4,773 
Leases848 (848)— 
Trade name1,294 (412)882 
Developed technologies17,278 (9,023)8,255 
Customer relationships8,379 (4,855)3,524 
Patents, trademarks, and other2,459 (1,148)1,311 
Total Intangibles$35,031 $(16,286)$18,745 
The Company acquired an insurance company in 2007, which originally included licenses in 23 states. These licenses were valued at $4.8 million. The Company is currently licensed in all 50 states, the District of Columbia and Puerto Rico. Insurance licenses are renewed annually upon payment of various fees assessed by the issuing state. Renewal costs are expensed as incurred. Insurance licenses are considered an indefinite-lived intangible asset given the planned renewal of the certificates of authority and applicable licenses for the foreseeable future.
Amortization expense associated with intangible assets was $5.3 million, $5.7 million, and $4.8 million for the years ended December 31, 2024, 2023, and 2022, respectively.
As of December 31, 2024, expected amortization expense relating to definite-lived intangible assets for each of the next five years and thereafter is as follows (in thousands):
Year ending December 31:
2025$4,423 
20261,370 
20271,272 
2028162 
2029162 
Thereafter277 
Total$7,666 
v3.25.0.1
Investment Securities (Notes)
 12 Months Ended
Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
Available-for sale securities are classified as short-term versus long-term investments based on whether they represent the investment of funds available for current operations. All available-for-sale securities are considered short-term in nature, with the exception of certain long-term investments that are being held for statutory requirements. Held-to-maturity securities are classified as short-term versus long-term investments based on their maturity dates. The amortized cost, gross unrealized holding gains and losses, and estimated fair value of long-term and short-term investments by major security type and class of security were as follows as of December 31, 2024 and 2023 (in thousands):
Amortized
Cost		Gross
Unrealized
Holding
Gains		Gross
Unrealized
Holding
Losses		Fair
Value
As of December 31, 2024
Long-term investments:
Held-to-maturity investments
U.S. treasury securities$373 $— $(1)$372 
$373 $— $(1)$372 
Short-term investments:
Available-for-sale investments
              U.S. treasury securities$70,175 $318 $(202)$70,291 
Mortgage-backed securities and collateralized mortgage obligations12,576 80 (60)12,596 
Other asset-backed securities15,830 134 (8)15,956 
Corporate bonds35,382 284 (43)35,623 
$133,963 $816 $(313)$134,466 
Held-to-maturity investments
U.S. Treasury securities$10,591 $16 $(1)$10,606 
              Certificates of deposit2,032 — — 2,032 
$12,623 $16 $(1)$12,638 
 Amortized
Cost		Gross
Unrealized
Holding
Gains		Gross
Unrealized
Holding
Losses		Fair
Value
As of December 31, 2023
Long-term investments:
Available-for-sale investments
Foreign deposits$11,869 $— $— $11,869 
$11,869 $— $— $11,869 
Held-to-maturity investments
U.S. treasury securities$997 $8 $— $1,005 
$997 $8 $— $1,005 
Short-term investments:
Available-for-sale investments
U.S. treasury securities$44,425 $326 $(64)$44,687 
Mortgage-backed securities and collateralized mortgage obligations10,460 69 (75)10,454 
Other asset-backed securities12,422 67 (53)12,436 
Corporate bonds36,404 332 (123)36,613 
$103,711 $794 $(315)$104,190 
Held-to-maturity investments
U.S. Treasury securities$13,179 $21 $(15)$13,185 
Certificates of deposit12,298 — — 12,298 
$25,477 $21 $(15)$25,483 
Maturities of investments classified as available-for-sale and held-to-maturity were as follows (in thousands):
 December 31, 2024
 Amortized
Cost		Fair
Value
Available-for-sale:
Due under one year$4,178 $4,196 
Due after one year through five years101,379 101,718 
$105,557 $105,914 
Available-for-sale collateralized:
Due under one year$3,823 $3,837 
Due after one year through five years20,691 20,865 
Due after five years through ten years3,614 3,565 
Due after ten years278 285 
$28,406 $28,552 
Held-to-maturity:
Due under one year$12,623 $12,638 
Due after one year through five years373 372 
$12,996 $13,010 
The following tables present the gross unrealized losses and related fair values for the Company's investment in available-for-sale securities, grouped by duration of time in a continuous unrealized loss position as of December 31, 2024 and December 31, 2023 (in thousands):
Less than 12 Months12 Months or MoreTotal
Fair ValueGross Unrealized LossesFair ValueGross Unrealized LossesFair ValueGross Unrealized Losses
As of December 31, 2024
U.S. treasury securities$27,769 $(202)$— $— $27,769 $(202)
Mortgage-backed securities and collateralized mortgage obligations1,538(20)1,359(40)2,897(60)
Other asset-backed securities186(1)1,737(7)1,923(8)
Corporate bonds6,461(40)736(3)7,197(43)
Total$35,954 $(263)$3,832 $(50)$39,786 $(313)
Less than 12 Months12 Months or MoreTotal
Fair ValueGross Unrealized LossesFair ValueGross Unrealized LossesFair ValueGross Unrealized Losses
As of December 31, 2023
U.S. treasury securities$20,772 $(64)$— $— $20,772 $(64)
Mortgage-backed securities and collateralized mortgage obligations2,385(4)2,220(71)4,605(75)
Other asset-backed securities1,486(1)4,986(52)6,472(53)
Corporate bonds1,178(1)11,491(122)12,669(123)
Total$25,821 $(70)$18,697 $(245)$44,518 $(315)
Unrealized losses on available-for-sale investments relate to interest rate changes. The Company does not expect any credit losses from its available-for-sale investments, considering the composition of the investment portfolio and the credit rating of these investments. For those securities, the Company determined it is not likely to, and does not intend to, sell prior to a potential recovery of the cost basis. The Company does not expect any credit losses from its held-to-maturity investments, considering the composition of the investment portfolio and the credit loss history of these investments.
Proceeds from the sales of fixed maturities classified as available-for-sale were $77.1 million and $114.7 million during the years ended December 31, 2024 and 2023, respectively.
v3.25.0.1
Other Investments (Notes)
 12 Months Ended
Dec. 31, 2024
Other Investments [Abstract]  
Other Investments . Other Investments
Preferred Stock Investment
The Company has invested $7.0 million in the preferred stock of a variable interest entity, Baystride, Inc., a U.S.-based privately held corporation operating in the pet food industry. The Company does not have power over the activities that most significantly impact the economic performance of the entity and is, therefore, not the primary beneficiary. The Company has the option to purchase all of the outstanding common stock issued by the entity in August 2027 at an amount approximating its expected fair value. The preferred stock investment in the entity is redeemable and, therefore, is accounted for as an available-for-sale debt security and measured at fair value at each balance sheet date — see Note 7.
Additionally, the Company has extended a $7.0 million revolving line of credit to the variable interest entity to fund its inventory purchases, which will increase annually by $2.0 million until the note’s maturity in 2027. Borrowing amounts are subject to limitations based on Baystride’s forecasted revenues and inventory balances. The Company's investment and amounts loaned under the line of credit are recorded in other long-term assets on its consolidated balance sheet. The outstanding loan balance under the line of credit, including accrued interest, was $1.6 million and $4.0 million as of December 31, 2024 and 2023, respectively. The Company has also entered into a series of agreements to provide ancillary services to, and receive reimbursement from, the variable interest entity at cost. The Company provided $0.3 million and $0.4 million of these services for the years ended December 31, 2024 and 2023, respectively.
Allowance for Credit Losses
The Company regularly evaluates its investments for expected credit losses. The Company considers past events, current conditions, and reasonable and supportable forecasts in estimating an allowance for credit losses. Additionally, the Company considers the ultimate collection of cash flows from its investments and whether the Company has the intent to sell, or if it is more likely than not the Company would be required to sell the security prior to recovery of its amortized cost. Such evaluations are revised as conditions change and new information becomes available. Based on these considerations, the Company established an allowance for credit losses related to its investment in the preferred stock of Baystride, Inc in 2023. This credit loss allowance was reversed in 2024 as the fair value of the Company's investment in Baystride, Inc. was determined to have recovered to an amount above the original investment amount. The following table presents a rollforward of the allowance for credit losses for this investment.
 December 31,
 20242023
Balance at beginning of period$(1,674)$— 
Recovery of (addition to) allowance for credit losses1,674 (1,674)
Balance at end of period$— $(1,674)
Investment in Joint Venture
In September 2018, the Company acquired a non-controlling equity interest in a joint venture in Australia, whereby it has committed to licensing certain intellectual property and contributing up to $2.2 million AUD upon the achievement of specific operational milestones over a period of at least four years from the agreement execution date. As of December 31, 2024, the Company has contributed $1.5 million AUD. This equity investment is accounted for using the equity method and is classified in other long-term assets on the Company's consolidated balance sheet. The Company's share of income and losses from this equity method investment is included in gain (loss) from investment in joint venture on its consolidated statement of operations. Also included in this line item are income and expenses associated with administrative services provided to the joint venture.
Equity Method Investments and Joint Ventures Disclosure [Text Block]
Investment in Joint Venture
In September 2018, the Company acquired a non-controlling equity interest in a joint venture in Australia, whereby it has committed to licensing certain intellectual property and contributing up to $2.2 million AUD upon the achievement of specific operational milestones over a period of at least four years from the agreement execution date. As of December 31, 2024, the Company has contributed $1.5 million AUD. This equity investment is accounted for using the equity method and is classified in other long-term assets on the Company's consolidated balance sheet. The Company's share of income and losses from this equity method investment is included in gain (loss) from investment in joint venture on its consolidated statement of operations. Also included in this line item are income and expenses associated with administrative services provided to the joint venture.
Accounts Receivable, Allowance for Credit Loss The following table presents a rollforward of the allowance for credit losses for this investment.
 December 31,
 20242023
Balance at beginning of period$(1,674)$— 
Recovery of (addition to) allowance for credit losses1,674 (1,674)
Balance at end of period$— $(1,674)
v3.25.0.1
Fair Value (Notes)
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Fair Value
Fair Value Disclosures
The following table summarizes, by major security type, the Company's assets that are measured at fair value on a recurring basis, and placement within the fair value hierarchy (in thousands):
 As of December 31, 2024
 Fair ValueLevel 1Level 2Level 3
Assets
Money market funds$91,534 $91,534 $— $— 
Fixed maturities:
Mortgage-backed securities and collateralized mortgage obligations12,596 — 12,596 — 
Other asset-backed securities15,956 — 15,956 — 
Corporate bonds35,623 — 35,623 — 
U.S. Treasury securities70,291 — 70,291 — 
Preferred stock investment7,916 — — 7,916 
Total$233,916 $91,534 $134,466 $7,916 
 As of December 31, 2023
 Fair ValueLevel 1Level 2Level 3
Assets
Money market funds$67,360 $67,360 $— $— 
Fixed maturities:
Mortgage-backed securities and collateralized mortgage obligations10,454 — 10,454 — 
Other asset-backed securities12,436 — 12,436 — 
Corporate bonds36,613 — 36,613 — 
Foreign deposits11,869 11,869 — — 
U.S. Treasury securities44,687 — 44,687 — 
Preferred stock investment5,326 — — 5,326 
Total$188,745 $79,229 $104,190 $5,326 
The Company measures the fair value of money market funds and foreign deposits, classified as Level 1, based on quoted prices in active markets for identical assets. The Company's fixed maturity investments classified as either Level 1 or Level 2 in the above tables are priced exclusively by external sources, including pricing vendors, dealers/market makers, and exchange-quoted prices. The fair value of the Company's fixed maturity investments classified as Level 2 is based on either recent trades in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. Held-to-maturity investments are carried at amortized cost and the fair value and changes in unrealized gains (losses) are disclosed in Note 5, Investments. The fair value of these investments is determined in the same manner as available-for-sale securities and are considered either a Level 1 or Level 2 measurement.
The Company's preferred stock investment (see Note 6) is accounted for as an available-for-sale debt security, and measured at fair value at each balance sheet date. The estimated fair value of the preferred stock investment is a Level 3 measurement, and is based on certain unobservable inputs such as the value of the underlying enterprise, volatility, time to liquidity, and market interest rates. An increase or decrease in any of these unobservable inputs would result in a change in the fair value measurement. The estimated fair value was $7.9 million and $5.3 million as of December 31, 2024 and 2023, respectively, and is recorded in other long-term assets on the Company's consolidated balance sheet.
The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers between levels for the years ended December 31, 2024 and 2023.
The following table presents the change in fair value of the Company’s investment carried at fair value and classified as Level 3 as of December 31, 2024 (in thousands):
 December 31,
 20242023
Balance at beginning of period$5,326 $4,115 
Unrealized gain included in other comprehensive income (loss)916 — 
Reversal of cumulative unrealized loss included in other comprehensive income (loss)— 2,885 
Recovery of (increase in) credit loss included in earnings1,674 (1,674)
Balance at end of period$7,916 $5,326 
Fair Value Disclosures - Other Assets and Liabilities
The Company's other long-term assets balance also included notes receivable of $4.3 million and $6.8 million as of December 31, 2024 and 2023, respectively, recorded at their estimated recoverable amount. The Company estimates that the carrying value of the notes receivable approximates their fair value. The estimated fair value represents a Level 3 measurement within the fair value hierarchy, and is based on market interest rates and the assessed creditworthiness of the third party.
The Company estimates the fair value of long-term debt based upon rates currently available to the Company for debt with similar terms and remaining maturities. This is a Level 3 measurement. Based upon the terms of the debt, the carrying amount of long-term debt approximated fair value at December 31, 2024.
v3.25.0.1
Commitment and Contingencies (Notes)
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Proceedings
From time to time the Company is or may become subject to various legal proceedings arising in the ordinary course of business, including proceedings against members, other entities or regulatory bodies. Estimated liabilities are recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. At this time, the Company does not believe any such matters to be material individually or in the aggregate. These views are subject to change following the outcome of future events or the results of future developments.
v3.25.0.1
Claims Reserve (Notes)
 12 Months Ended
Dec. 31, 2024
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]  
Reserve for Veterinary Invoices
The reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary claims that have not been paid prior to the reporting date. The reserve also includes the Company's estimate of related internal processing costs. The reserve estimate involves actuarial projections, and is based on management's assessment of facts and circumstances currently known, and assumptions about anticipated patterns. The Company uses generally accepted actuarial methodologies, such as paid loss development methods, in estimating the amount of the reserve for veterinary invoices. The reserve is made for each of the Company's segments, subscription and other business, and is continually refined as the Company receives and pays veterinary invoices. Changes in management's assumptions and estimates may have a relatively large impact to the reserve and associated expense.
Reserve for veterinary invoices
Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands):
 Year Ended December 31,
Subscription202420232022
Reserve at beginning of year$31,548 $21,543 $22,407 
Veterinary invoices during the period related to:
Current year623,928 540,396 439,679 
Prior years500 2,800 (2,799)
Total veterinary invoice expense624,428 543,196 436,880 
Amounts paid during the period related to:
Current year598,593 506,294 414,778 
Prior years30,875 23,001 18,739 
Total paid629,468 529,295 433,517 
Non-cash expenses3,424 3,896 4,227 
Reserve at end of period$23,084 $31,548 $21,543 
The Company had unfavorable development on veterinary invoice reserves of $0.5 million for the year ended December 31, 2024, including favorable development of $1.2 million attributable to accident year 2023 and unfavorable development of $1.7 million attributable to accident year 2022 and prior. The favorable development for accident year 2023 was primarily driven by faster reporting patterns of claims than initially anticipated. The unfavorable development for accident year 2022 and prior was driven by higher than expected frequency of claims. Non-cash expenses are primarily comprised of stock-based compensation for employees performing claims processing related duties.


Summarized below are the changes in total liability for the Company's other business segment (in thousands):
 Year Ended December 31,
Other Business202420232022
Reserve at beginning of year$31,690 $22,191 $17,264 
Veterinary invoices during the period related to:
Current year326,018 287,361 211,729 
Prior years(1,298)498 1,128 
Total veterinary invoice expense324,720 287,859 212,857 
Amounts paid during the period related to:
Current year298,596 256,616 190,031 
Prior years29,263 21,744 17,899 
Total paid327,859 278,360 207,930 
Non-cash expenses— — — 
Reserve at end of period$28,551 $31,690 $22,191 

The Company had favorable development on veterinary invoice reserves for the other business segment of $1.3 million for the year ended December 31, 2024, including favorable development on veterinary invoice reserves of $1.1 million attributable to accident year 2023 and favorable development of $0.2 million attributable to accident year 2022 and prior. The favorable development for accident year 2023 and 2022 was driven by faster paid loss development factors than originally estimated for Pets Best, as well as the estimated impact of the roll-off of a portion of the business.
Reserve for veterinary invoices, by year of occurrence

In the following tables, the cumulative veterinary invoice expenses represent the total expense from received invoices as of December 31, 2024, by year the veterinary invoice relates to, referred to as the year of occurrence. Information for years 2021 through 2023 is provided as required supplementary information. Amounts in these tables are presented on a constant currency basis to remove the impact of changes in the foreign currency exchange rate on development. The cumulative expenses as of the end of each year are revalued using the currency exchange rate as of December 31, 2024. Due to variability in internal and external sources of claims data, and the lack of comparability of claim count information between those sources, it is impractical for the Company to disclose claim frequency information. As such, the cumulative number of veterinary invoices received is not included in the disclosures below.

The following table summarizes the development of veterinary invoice expense, on a constant currency basis, for the Company's subscription business segment by year of occurrence (in thousands, except for cumulative number of veterinary invoices data):
Cumulative veterinary invoice expensesReserve
As of December 31,As of December 31,
Subscription20212022202320242024
Year of Occurrence(unaudited)(unaudited)(unaudited)
2021$348,851 $346,611 $347,130 $347,828 $— 
2022$431,384 $432,694 $433,132 $— 
2023$533,742 $532,630 $1,174 
2024$617,853 $21,910 
$1,931,443 $23,084 

The following table summarizes the development of veterinary invoice expense, on a constant currency basis, for the Company's other business segment by year of occurrence (in thousands, except for cumulative number of veterinary invoices data):
Cumulative veterinary invoice expensesReserve
As of December 31,As of December 31,
Other Business20212022202320242024
Year of Occurrence(unaudited)(unaudited)(unaudited)
2021$129,797 $130,632 $130,559 $130,691 $— 
2022$211,708 $212,147 $211,768 $16 
2023$287,344 $286,241 $1,113 
2024$326,007 $27,422 
$954,707 $28,551 

Cumulative paid veterinary invoice expense

In the following tables, amounts are by the year the veterinary invoice relates to, referred to as the year of occurrence. Amounts in these tables are presented on a constant currency basis to remove the impact of changes in the foreign currency exchange rate. The cumulative amounts paid as of the end of each year are revalued using the currency exchange rate as of December 31, 2024. Information for years 2021 through 2023 is provided as required supplementary information.
The following table summarizes the amounts paid for veterinary invoices, inclusive of related internal processing costs and reported on a constant currency basis, for the subscription segment (in thousands):
Year Ended December 31,
Subscription2021202220232024
Year of Occurrence(unaudited)(unaudited)(unaudited)
2021$329,166 $345,748 $347,130 $347,828 
2022$410,869 $431,371 $433,132 
2023$503,819 $531,456 
2024$595,943 
$1,908,359 
Total amounts unpaid and recorded as a liability$23,084 

The following table summarizes the amounts paid for veterinary invoices, inclusive of related internal processing costs and reported on a constant currency basis, for the other business segment (in thousands):
Year Ended December 31,
Other Business2021202220232024
Year of Occurrence(unaudited)(unaudited)(unaudited)
2021$112,545 $130,139 $130,559 $130,691 
2022$190,010 $211,202 $211,752 
2023$256,600 $285,129 
2024$298,584 
$926,156 
Total amounts unpaid and recorded as a liability$28,551 
v3.25.0.1
Debt (Notes)
 12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Long-Term Debt [Text Block] Debt
On March 25, 2022, the Company entered into a credit agreement with Piper Sandler Finance, LLC, acting as the administrative agent, that provides the Company with $150.0 million in credit (the Credit Facility) consisting of:
(a) an initial term loan in an aggregate principal amount of $60.0 million (Initial Term Loan), which was funded at closing;
(b) commitments for delayed draw term loans in an aggregate principal amount not in excess of $75.0 million (Delayed Draw Term Loans, and together with the Initial Term Loan, the Term Loans), which may be drawn from time to time until September 25, 2023. On December 29, 2022, February 17, 2023, and September 21, 2023, the Company borrowed Delayed Draw Term loans of $15.0 million, $35.0 million, and $25.0 million, respectively; and
(c) commitments for revolving loans in an aggregate principal amount at any time outstanding not in excess of $15.0 million (Revolving Loans), which may be drawn at any time prior to March 25, 2027.
The Credit Facility bears interest at a floating base rate plus an applicable margin. The stated interest rate as of December 31, 2024 was approximately 9.5% for the original $60.0 million term loan and for the aggregate $75.0 million term loans. The Company incurred total debt issuance cost of approximately $5.9 million, which is reported in the consolidated balance sheet as a direct reduction from the carrying amount of the Credit Facility, and is amortized as interest expense over the term of five years.
The Credit Facility is secured by substantially all assets of the Company and its subsidiaries. Proceeds from the Credit Facility may be used for permitted acquisitions and investments, working capital and other general corporate purposes. The Credit Agreement contains financial and other covenants. As of December 31, 2024, the Company was in compliance with all financial and other covenants.
To the extent not previously paid, the Initial Term Loan is due and payable on March 25, 2027, the Delayed Draw Term Loans are due and payable on the earlier of the five-year anniversary of their initial funding or March 25, 2028, and Revolving Loans are due and payable on March 25, 2027. The Company must repay 0.25% of any then-outstanding Term Loans, together with accrued and unpaid interest, on a quarterly basis.
Future principal payments on outstanding borrowings as of December 31, 2024 are as follows (in thousands):
Year Ending December 31,December 31, 2024
20251,350 
20261,350 
202772,113 
202857,125 
Total$131,938 
v3.25.0.1
Stock-based Compensation (Notes)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation Stock-Based Compensation
Stock-based compensation expense includes restricted stock units granted to employees and other service providers and has been reported in the Company’s consolidated statements of operations depending on the function performed by the employee or other service provider. Stock-based compensation expense recognized in each category of the consolidated statements of operations for the years ended December 31, 2024, 2023 and 2022 was as follows (in thousands):
 Year Ended December 31,
 202420232022
Veterinary invoice expense$3,460 $3,667 $4,145 
Other cost of revenue2,063 1,612 2,339 
Technology and development4,934 2,846 4,742 
General and administrative15,696 17,717 12,831 
New pet acquisition expense7,279 7,319 9,336 
Total expensed stock-based compensation33,432 33,161 33,393 
Capitalized stock-based compensation505 2,135 1,633 
Total stock-based compensation$33,937 $35,296 $35,026 

Stock Options
The grant date fair value of stock option awards are estimated on the date of grant using the Black-Scholes option-pricing model. The Company did not grant any new stock options during the years ended December 31, 2024, 2023, and 2022.
The following table presents information regarding stock options granted, exercised and forfeited for the periods presented:
Number
of
Options		Weighted Average
Exercise
Price per Share		Aggregate
Intrinsic
Value
(in thousands)
Outstanding as of January 1, 2022807,205 $13.39 $95,765 
Granted— — — 
Exercised(174,721)12.82 10,931 
Forfeited(2,834)18.87 — 
Outstanding as of December 31, 2022629,650 13.53 21,410 
Granted— — — 
Exercised(213,848)12.47 3,720 
Forfeited(6,832)12.80 — 
Outstanding as of December 31, 2023408,970 14.09 6,715 
Granted— — — 
Exercised(61,136)12.91 1,590 
Expired(500)14.93 — 
Outstanding as of December 31, 2024347,334 14.30 11,775 
Exercisable at December 31, 2024347,334 $14.30 $11,775 
As of December 31, 2024, stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 1.7 years.

The Company has not granted any new stock options since 2017 and all outstanding options vested prior to January 1, 2022.
Restricted Stock Units
A summary of the Company’s restricted stock unit activity for the years ended December 31, 2024, 2023 and 2022 is as follows:
Number of 
Shares		Weighted Average
Grant Date Fair Value per
Share
Unvested shares as of January 1, 20221,087,627 $78.94 
Granted623,401 84.11 
Vested(516,077)72.81 
Forfeited(82,399)81.91 
Unvested shares as of December 31, 20221,112,552 84.46 
Granted366,870 26.77 
Vested(669,413)72.52 
Forfeited(95,627)79.60 
Unvested shares as of December 31, 2023714,382 66.64 
Granted957,168 29.21 
Vested(629,217)57.46 
Forfeited(71,594)44.00 
Unvested shares as of December 31, 2024970,739 $37.35 
v3.25.0.1
Stockholder's Equity (Notes)
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Stockholders' Equity Stockholders’ Equity
Common Stock and Preferred Stock
As of December 31, 2024, the Company had 100,000,000 shares of common stock authorized and 42,488,445 shares of common stock outstanding. Holders of common stock are entitled to one vote on each matter properly submitted to the stockholders of the Company except those related to matters concerning possible outstanding preferred stock. At December 31, 2024, the Company had 10,000,000 shares of undesignated preferred stock authorized for future issuance and did not have any outstanding shares of preferred stock. The holders of common stock are also entitled to receive dividends as and when declared by the board of directors of the Company (the Board), whenever funds are legally available. These rights are subordinate to the dividend rights of holders of any senior classes of stock outstanding at the time. The Company does not intend to declare or pay any cash dividends in the foreseeable future.
Share Repurchase Program
In April 2021, the Board approved a share repurchase program, pursuant to which the Company may, between May 2021 and May 2026, repurchase outstanding shares of the Company's common stock. The Company repurchased no shares during the year ended December 31, 2024 and 2023.
v3.25.0.1
Segments (Notes)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segments Segments
The Company has two reporting segments: subscription business and other business. The subscription business segment consists of aggregated operating segments with products that have been created to meet the needs of their distribution channels and have similar target margin profiles. This segment generates revenue primarily from subscription payments related to the Company's direct-to-consumer products. The other business segment generates revenue primarily by underwriting policies on behalf of third parties and has a different margin profile than the Company's subscription business segment. The Company does not undertake marketing efforts for these policies and has a business-to-business relationship with these third-parties.
The Company's chief operating decision maker is our Chief Executive Officer. The chief operating decision maker reviews revenue and operating income (loss) to evaluate segment performance. Revenue, veterinary invoice expense, other cost of revenue, new pet acquisition expenses, and goodwill impairment charges are generally directly attributed to each segment. Other operating expenses, such as technology and development expense, general and administrative expense, and depreciation and amortization, are generally allocated proportionately based on revenue in each segment. Interest and other expenses and income taxes are not allocated to the segments, nor included in the measure of segment profit or loss. The Company does not analyze discrete segment balance sheet information related to long-term assets.
Operating loss of the Company’s segments was as follows (in thousands):
Year Ended December 31,
202420232022
Subscription business:
Revenue$856,521 $712,906 $596,610 
Veterinary invoice expense624,428 543,196 436,880 
Other cost of revenue82,423 70,490 60,804 
Technology and development20,822 13,765 16,555 
General and administrative42,457 36,256 25,964 
New pet acquisition expense71,240 77,172 88,959 
Goodwill impairment charges5,299 — — 
Depreciation and amortization10,970 8,021 7,205 
Subscription business operating loss(1,118)(35,994)(39,757)
Other business:
Revenue429,163 395,699 308,569 
Veterinary invoice expense324,720 287,859 212,857 
Other cost of revenue75,315 76,044 72,453 
Technology and development10,433 7,638 8,578 
General and administrative21,274 23,951 13,415 
New pet acquisition expense139 200 541 
Depreciation and amortization5,496 4,453 3,716 
Other business operating loss(8,214)(4,446)(2,991)
Gain (loss) from investment in joint venture(182)(219)(253)
Total operating loss(9,514)(40,659)(43,001)
Interest expense14,498 12,077 4,267 
Other expense (income), net(14,374)(7,701)(3,072)
Loss before income taxes$(9,638)$(45,035)$(44,196)
The following table presents the Company’s revenue by geographic region of the member (in thousands):
 Year Ended December 31,
 202420232022
United States$1,073,150 $935,312 $764,349 
Canada and other212,534 173,293 140,830 
Total revenue$1,285,684 $1,108,605 $905,179 
Substantially all of the Company’s long-lived assets were located in the United States as of December 31, 2024 and 2023.
v3.25.0.1
Dividend Restrictions Statutory Surplus (Notes)
 12 Months Ended
Dec. 31, 2024
Insurance [Abstract]  
Dividend Restrictions And Statutory Surplus Dividend Restrictions and Statutory Surplus
The Company’s business operations are conducted through subsidiaries, one of which is an insurance company domiciled in New York, American Pet Insurance Company (APIC), and three of which are segregated cell businesses, Wyndham Segregated Accounts AX, Trupanion Germany, and Trupanion Switzerland, located in Bermuda. In 2022, the Company incorporated a new wholly-owned insurance subsidiary, GPIC Insurance Company (GPIC), domiciled in Canada. In 2021, the Company established two new wholly-owned insurance subsidiaries in the United States, ZPIC Insurance Company (ZPIC) and QPIC Insurance Company (QPIC), domiciled in Missouri and Nebraska, respectively. In addition to general state law restrictions on payments of dividends and other distributions to stockholders applicable to all corporations, insurance companies are subject to further regulations that, among other things, may require such companies to maintain certain levels of equity and restrict the amount of dividends and other distributions that may be paid to their parent corporations.
Applicable regulations generally restrict the ability of the insurance entities to pay dividends to its holding company parent. These restrictions are based in part on the prior year’s statutory income and surplus. In the United States, dividends up to specified levels are generally considered ordinary and may be paid without prior approval. Dividends, in larger amounts, known as extraordinary dividends, are subject to approval by the insurer's domiciliary state regulator. An extraordinary dividend or distribution is generally defined as a dividend or distribution that, in the aggregate in any 12-month period, exceeds the lesser of (i) 10% of surplus as of the preceding December 31 or (ii) the insurer’s adjusted net investment income for the 12-month period immediately preceding the declaration or distribution of the current dividend increased by the excess, if any, of net investment income over dividends declared or distributed during the period commencing thirty-six months prior to the declaration or distribution of the current dividend and ending twelve months prior thereto, and not including realized capital gains. APIC paid dividends of $4.2 million and $7.6 million to the Company during the years ended December 31, 2024 and 2023, respectively, and no dividends during the year ended December 31, 2022.
The Company's insurance subsidiaries in Bermuda are regulated by the Bermuda Monetary Authority. Under the Bermuda Companies Act of 1981, as amended, a Bermuda company may not declare or pay a dividend or make a distribution out of contributed surplus if there are reasonable grounds for believing that: (a) the company is, or would be after the payment, unable to pay its liabilities as they become due; or (b) the realizable value of the company’s assets would thereby be less than its liabilities. The Segregated Accounts Company Act of 2000 further requires that dividends out of a segregated account can only be paid to the extent that the cell remains solvent. The value of its assets must remain greater than the aggregate of its liabilities, issued share capital, and share premium accounts. Per our contractual agreements with Wyndham Insurance Company (SAC) Limited, the allowable dividend is equivalent to the positive undistributed profit attributable to the shares. Wyndham Segregated Account AX paid the Company a dividend of $8.6 million, $7.3 million, and $6.9 million during the years ended December 31, 2024, 2023 and 2022, respectfully.
The statutory net income for 2024, 2023 and 2022 and statutory capital and surplus at December 31, 2024, 2023 and 2022, for APIC were as follows (in thousands):
 As of December 31,
 202420232022
Statutory net income$49,007 $40,076 $35,227 
Statutory capital and surplus$245,484 $199,613 $162,232 
As of December 31, 2024, APIC maintained $245.5 million of statutory capital and surplus which was above the company action level risk-based capital requirement of $105.3 million.
During the year ended December 31, 2024, the Company funded $1.1 million and $0.2 million of statutory capital to APIC and ZPIC, respectively, and no capital to GPIC. During the year ended December 31, 2023, the Company funded $3.8 million, $0.2 million and CAD $8.5 million of statutory capital to APIC, ZPIC and GPIC, respectively. ZPIC and GPIC will each be required to maintain a level of surplus as determined by their respective domiciliary regulators. During 2024, the Company fully dissolved QPIC, which included total distributions of $7.0 million of previously required capital to Trupanion, Inc.
As of December 31, 2024, the Company had $11.5 million on deposit with various states in which it is licensed to write policies.
v3.25.0.1
Retirement Plan (Notes)
 12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Employee Benefits Employee BenefitsThe Company has a 401(k) plan for its U.S. employees. The plan allows employees to contribute a percentage of their pretax earnings annually, subject to limitations imposed by the Internal Revenue Service. The plan also allows the Company to make a matching contribution, subject to certain limitations. As of December 31, 2024, the Company has made no matching contributions to the 401(k) plan.
v3.25.0.1
Schedule 1-Parent Only Disclosures [Schedule] (Notes)
 12 Months Ended
Dec. 31, 2024
Condensed Financial Information Disclosure [Abstract]  
Schedule 1 - Condensed Financial Information of Registrant
Trupanion, Inc.
Condensed Statements of Operations and Comprehensive Loss
(Parent Company Only, in thousands)
 Year Ended December 31,
 202420232022
Expenses:
Veterinary invoice expense$290 $253 $4,144 
Other cost of revenue347 240 2,340 
Technology and development1,934 1,507 4,930 
General and administrative3,915 5,345 16,346 
New pet acquisition expense1,422 806 9,351 
Depreciation and amortization941 494 289 
Total expenses8,849 8,645 37,400 
Gain (loss) from investment in joint venture192 (237)(192)
Operating loss9,041 (8,882)(37,592)
Interest expense14,345 11,998 4,255 
Other expense (income), net(16,303)(14,442)(8,047)
Loss before income taxes and loss in undistributed earnings of subsidiaries(7,083)(6,438)(33,800)
Income tax benefit18,939 15,766 14,544 
Loss in undistributed earnings of subsidiaries(21,489)(54,021)(25,416)
Net loss$(9,633)$(44,693)$(44,672)
Other comprehensive income (loss), net of taxes:
Other comprehensive income (loss) of subsidiaries(3,015)6,704 (9,378)
Other comprehensive income (loss)(3,015)6,704 (9,378)
Comprehensive loss$(12,648)$(37,989)$(54,050)
Trupanion, Inc.
Condensed Balance Sheets
(Parent Company Only)
(In thousands, except share data)
 December 31,
 20242023
Assets
Current assets:
Cash and cash equivalents$11,951 $10,994 
Accounts and other receivables1,194 1 
Prepaid expenses and other assets815 804 
Total current assets13,960 11,799 
Restricted cash25,406 22,963 
Property and equipment, net4,180 3,981 
Intangible assets, net5,869 5,808 
Other long-term assets12,415 12,540 
Advances to and investments in subsidiaries392,898 377,031 
Total assets$454,728 $434,122 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable, accrued liabilities, and other current liabilities$1,488 $336 
Long-term debt - current portion1,350 1,350 
Total current liabilities2,838 1,686 
Long-term debt127,537 127,580 
Deferred tax liabilities1,057 1,106 
Other liabilities28 28 
Total liabilities131,460 130,400 
Stockholders’ equity:
Common stock: $0.00001 par value per share, 100,000,000 shares authorized; 43,516,631 and 42,888,445 shares issued and outstanding at December 31, 2024; 42,887,052 and 41,858,866 shares issued and outstanding at December 31, 2023
— — 
Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding
— — 
Additional paid-in capital568,302 536,108 
Accumulated other comprehensive income (loss)(2,612)403 
Accumulated deficit(225,888)(216,255)
Treasury stock, at cost: 1,028,186 shares at December 31, 2024 and 2023
(16,534)(16,534)
Total stockholders’ equity323,268 303,722 
Total liabilities and stockholders’ equity$454,728 $434,122 
Trupanion, Inc.
Condensed Statements of Cash Flows
(Parent Company Only, in thousands)
 Year Ended December 31,
 202420232022
Operating activities
Net loss$(9,633)$(44,693)$(44,672)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Loss attributable to investments in subsidiaries8,707 39,184 19,331 
Dividends from subsidiaries12,782 14,837 6,942 
Depreciation and amortization941 494 289 
Stock-based compensation expense6,178 4,575 33,393 
Other, net(395)4,200 533 
Changes in operating assets and liabilities507 6,194 (166)
Net cash provided by operating activities19,087 24,791 15,650 
Investing activities
Cash paid in business acquisition, net of cash acquired— — (15,034)
Purchases of property, equipment, and internal-use software(1,201)(172)(516)
Advances to and investments in subsidiaries(13,526)(87,198)(71,671)
Other2,157 1,586 (1,598)
Net cash used in investing activities(12,570)(85,784)(88,819)
Financing activities
Proceeds from debt financing, net of financing fees— 59,972 69,138 
Repayment of debt financing(1,350)(1,225)(487)
Repurchases of common stock— — (5,755)
Proceeds from exercise of stock options752 2,655 2,290 
Shares withheld to satisfy tax withholding(2,519)(1,536)(4,359)
Net cash (used in) provided by financing activities(3,117)59,866 60,827 
Net change in cash, cash equivalents, and restricted cash3,400 (1,127)(12,342)
Cash, cash equivalents, and restricted cash at beginning of period33,957 35,084 47,426 
Cash, cash equivalents, and restricted cash at end of period$37,357 $33,957 $35,084 

1. Organization and Presentation
The accompanying condensed financial statements present the financial position, results of operations and cash flows for Trupanion, Inc. These condensed unconsolidated financial statements should be read in conjunction with the consolidated financial statements of Trupanion, Inc. and its subsidiaries and the notes thereto (the Consolidated Financial Statements). Investments in subsidiaries are accounted for using the equity method of accounting. Trupanion, Inc. received cash dividends from subsidiaries of $12.8 million, $14.9 million and $6.9 million for the years ended December 31, 2024, 2023 and 2022, respectively. These cash dividends were recorded within Trupanion, Inc.'s other income and were eliminated within the consolidated financial statements of Trupanion, Inc.
Additional information about Trupanion, Inc.’s accounting policies pertaining to intangible assets, commitments and contingencies, stock-based compensation, stockholders’ equity, and income taxes are set forth in Notes 4, 8, 11, 12, and 16, respectively, to the Consolidated Financial Statements.
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business and Basis of Presentation
Description of Business
Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the "Company") provides medical insurance for cats and dogs in the United States, Canada, certain countries in Continental Europe, and Australia. Through our data-driven, vertically-integrated approach, we develop and offer high value medical insurance products, priced specifically for each pet’s unique characteristics and coverage level.
Basis of Presentation
The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates [Policy Text Block]
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At times, cash on deposit may be in excess of the applicable federal deposit insurance corporation limits.
The Company considers any cash account not held in trust for a third party that is contractually restricted to withdrawal or use to be restricted cash. The Company is required to maintain certain restricted cash balances to comply with insurance company regulations. As of December 31, 2024, the Company was in compliance with all requirements.
Trade and Other Accounts Receivable, Policy [Policy Text Block]
Accounts and Other Receivables
Accounts and other receivables are comprised of trade receivables and other miscellaneous receivables and are carried at their estimated collectible amounts. Trade receivables are primarily related to the Company’s other business segment where the Company generates revenue from underwriting policies through unaffiliated general agents. These policies are typically annual policies, with monthly payment terms through the end of the twelve-month period. The Company had $252.0 million and $249.8 million accounts receivable associated with underwriting these policies as of December 31, 2024 and 2023, respectively. During the year ended December 31, 2023, the Company incurred a non-recurring $3.8 million settlement of accounts receivable due to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers.
Deferred Policy Acquisition Costs, Policy [Policy Text Block]
Deferred Acquisition Costs
The Company incurs certain costs, including premium taxes, enrollment-based bonuses, and referral fees that directly relate to the successful acquisition of new or renewal customer contracts. These costs are deferred and are included in prepaid expenses and other assets on the consolidated balance sheet and amortized over the related policy term to the applicable financial statement line item, either new pet acquisition expense or other cost of revenue. Deferred acquisition costs as of December 31, 2024 and 2023 were $7.5 million and $7.4 million, respectively. Amortized deferred acquisition costs classified within new pet acquisition expense amounted to $6.9 million, $6.0 million, and $4.9 million and amortized deferred acquisition costs classified within other cost of revenue amounted to $51.5 million, $45.6 million, and $33.9 million, for the years ended December 31, 2024, 2023, and 2022, respectively.
Investment, Policy [Policy Text Block]
Investments
The Company invests in investment grade fixed maturity securities of varying maturities. Available-for-sale securities are reported at fair value with unrealized gains and losses included in accumulated other comprehensive income (loss). Held-to-maturity securities are reported at amortized cost. Premiums or discounts on fixed maturity securities are amortized or accreted over the life of the security and included in interest income. There were $0.4 million in realized gains and $0.3 million in realized losses on sales of fixed maturity securities during the year ended December 31, 2024, $0.3 million in realized gains and $0.9 million in realized losses on sales of fixed maturity securities during the year ended December 31, 2023, and no realized gains or losses on sales of fixed maturity securities during the years ended December 31, 2022.
Each reporting period, the Company evaluates whether declines in fair value of its investments below carrying value are the result of expected credit losses. This evaluation includes the Company's ability and intent to hold these investments until recovery of carrying value occurs, including an evaluation of all available information relevant to the collectability of the security, including past events, current conditions, and reasonable and supportable forecasts. Expected credit losses are recorded as an allowance through other expense (income), net on the Company's consolidated statements of operations.
Fair Value Measurement, Policy [Policy Text Block]
Fair Value of Financial Instruments
The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:
Level 1 - Quoted prices in active markets for identical assets or liabilities
Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly
Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability
The Company's financial instruments, in addition to those presented in Note 7, Fair Value, include cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities. The carrying amounts of accounts receivable, accounts payable, and accrued liabilities approximate fair value because of the short-term nature of these instruments.
Property, Plant and Equipment, Policy [Policy Text Block]
Property, Equipment, and Internal-Use Software
Property, equipment, and internal-use software primarily consists of building, land and land improvements, office equipment, internal-use software related to the Company’s website, and internal support systems. Internal-use software is capitalized during the application development stage of the project. Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of the respective asset:
LandNot depreciable
Land improvements10years
Building39years
Software3to5years
Office equipment3to5years
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]
Goodwill and Intangible Assets
Goodwill and indefinite-lived intangible assets are not amortized. The Company reviews these assets for impairment at least annually or if indicators of potential impairment exist. Acquired finite-lived intangibles are amortized on a straight-line basis over the estimated useful lives of the assets. The Company recognized impairment charges on goodwill totaling $5.2 million during the year ended December 31, 2024, and no goodwill impairment charges in the years ended December 31, 2023 and 2022. The Company recognized no impairment on indefinite-lived intangible assets during the years ended December 31, 2024, 2023, and 2022. See Note 4 to these financial statements for further details on goodwill and related impairment charges.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]
Asset Impairment
Long-lived assets, including property, equipment, internal-use software, and finite-lived intangible assets, are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Should an impairment exist, the impairment loss would be measured as the amount the asset's carrying value exceeds its fair value. The Company has recognized no impairment loss on long-lived assets, including property, equipment, internal-use software, and finite-lived intangible assets for the years ended December 31, 2024, 2023, and 2022.
Liability Reserve Estimate, Policy [Policy Text Block]
Reserve for Veterinary Invoices
Reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary claims that have been incurred but not yet paid as of the reporting date. The reserve also includes the Company's estimate of related internal processing costs. To determine the accrual, the Company makes assumptions based on its historical experience, including the number of veterinary invoices it expects to receive, the average cost of those veterinary invoices, the length of time between the date of the veterinary invoice and the date the Company receives it, the member's chosen deductible, and the Company's expected cost to process and administer the payments. As of each balance sheet date, the Company reevaluates its reserve and adjusts the estimate for new information.
Deferred Revenue, Policy [Policy Text Block]
Deferred Revenue
Deferred revenue is primarily related to the Company’s other business segment where the Company generates revenue from underwriting policies through unaffiliated general agents. These policies are typically annual policies for which revenue is recognized pro-rata over the twelve-month policy period. Deferred revenue also consists of subscription payments received or billed in advance of the subscription services within the Company's subscription business.
Revenue Recognition, Policy [Policy Text Block]
Revenue Recognition
Revenue is recognized pro-rata over the term of the customer contracts. The Company generates revenue primarily from subscription payments and through underwriting policies for unaffiliated general agents. For the year ended December 31, 2024, premiums from policies sourced by general agents accounted for 32% of our total revenue, and one general agent sourced members whose premiums accounted for over 10% of our total revenue.
Cost of Sales, Policy [Policy Text Block]
Veterinary Invoice Expense
Veterinary invoice expense includes the Company’s costs to review and pay veterinary invoices, administer the payments, and provide member services, and other operating expenses directly or indirectly related to this process. The Company also accrues for veterinary claims that have been incurred but not yet paid and the estimated cost of processing these invoices. Veterinary invoice expense also includes amounts paid by unaffiliated general agents on our behalf, and an estimate of amounts incurred and not yet paid for the other business segment.
Other Costs of Revenue, Policy [Policy Text Block]
Other Cost of Revenue
Other cost of revenue for the subscription business segment includes direct and indirect member service expenses, Territory Partner renewal fees, credit card transaction fees and premium tax expenses. Other cost of revenue for the other business segment includes the commissions the Company pays to unaffiliated general agents and costs to administer the programs in the other business segment.
Research and Development Expense, Policy [Policy Text Block]
Technology and Development
Technology and development expenses primarily consist of personnel costs and related expenses for the Company's technology staff, which includes information technology development and infrastructure support and third-party services. It also includes expenses associated with development of new products and offerings.
Selling, General and Administrative Expenses, Policy [Policy Text Block]
General and Administrative
General and administrative expenses consist primarily of personnel costs and related expenses for the Company’s finance, actuarial, human resources, legal, regulatory, and general management functions, as well as facilities and professional services.
New Pet Acquisition Expense
New pet acquisition expense primarily consists of costs, including employee compensation, to educate veterinarians and consumers about the benefits of Trupanion, to generate leads and to convert leads into enrolled pets, as well as print, online and promotional advertising costs.
Nonoperating Income (Expense)
Other Expense (Income), Net
Other income, net, totaled $14.4 million, $7.7 million, and $3.1 million, including interest income of $12.4 million, $9.0 million, and $3.0 million for the years ended December 31, 2024, 2023, and 2022. In 2023 other income was offset by a credit loss of $1.7 million related to the Company's preferred stock investment (refer to Note 6, Other Investments). This loss was subsequently determined to be recovered, and reversed through other income, during the year ended December 31, 2024.
Advertising Costs, Policy [Policy Text Block]
Advertising
Advertising costs are expensed as incurred. Advertising costs amounted to $13.3 million, $16.9 million and $25.5 million, in the years ended December 31, 2024, 2023 and 2022, respectively.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Stock-Based Compensation
Compensation expense related to stock-based transactions, including employee and non-employee stock option awards, restricted stock awards, and restricted stock units, is measured and recognized in the financial statements based on fair value. The fair value of restricted stock awards and restricted stock units is the common stock price as of the measurement date.
Stock-based compensation expense for stock options and restricted stock units is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes forfeitures when they occur.
Income Tax, Policy [Policy Text Block]
Income Taxes
The Company uses the asset and liability approach for accounting and reporting income taxes. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities, and their respective tax bases, operating loss, and tax credit carryforwards.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a tax rate change is recognized in the period that includes the enactment date. Valuation allowances are provided for when it is considered more likely than not that deferred tax assets will not be realized.
The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than a 50% likelihood of being realized. Penalties and interest are classified as a component of income taxes.
Foreign Currency Transactions and Translations Policy [Policy Text Block]
Foreign Currency Translation
The Company’s consolidated financial statements are reported in U.S. dollars. Assets and liabilities denominated in foreign currencies were translated to U.S. dollars, the reporting currency, at the exchange rates in effect on the balance sheet date. Revenue and expenses denominated in foreign currencies were translated to U.S. dollars using a weighted average rate for the relevant reporting period. Cumulative translation adjustments of $(3.1) million, $(0.1) million, and $(2.8) million were recorded in accumulated other comprehensive loss (income) as of December 31, 2024, 2023, and 2022, respectively.
Reinsurance Accounting Policy [Policy Text Block]
Insurance Operations
Effective January 1, 2015, the Company formed a segregated account in Bermuda as part of Wyndham Insurance Company (SAC) Limited (WICL) and entered into a revised fronting and reinsurance arrangement with Accelerant Insurance Company of Canada, formerly known as Omega General Insurance Company, to include its newly formed segregated account. The Company maintains all risk with the business written in Canada and consolidates the entity in its financial statements. Dividends are allowed subject to the Segregated Accounts Company Act of 2000, which allows for dividends only to the extent that the entity remains solvent and the value of its assets remain greater than the aggregate of its liabilities and its issued share capital and share premium accounts.
For the Company’s Canadian business, all plans are written by Accelerant and the risk is assumed by the Company through a fronting and reinsurance agreement. Premiums are recognized and earned pro rata over the terms of the related customer contracts. Revenue recognized from the agreement in 2024, 2023, and 2022 was $206.7 million, $167.6 million and $135.9 million, respectively, and deferred revenue relating to this arrangement at December 31, 2024 and 2023 was $11.3 million and $9.5 million, respectively. Reinsurance revenue was 16%, 15%, and 15% of total revenue in 2024, 2023, and 2022, respectively. Cash designated for the purpose of paying claims related to this reinsurance agreement was $7.2 million and $11.2 million at December 31, 2024 and 2023, respectively. In addition, as required by the Office of the Superintendent of Financial Institutions regulations related to the Company’s reinsurance agreement with Accelerant, the Company is required to fund a Canadian Trust account with the greater of CAD $2.0 million or 120% of unearned Canadian premium plus 20% of outstanding Canadian claims, including all incurred but not reported claims. As of December 31, 2024, the account balance was CAD $19.9 million and the Company was in compliance with all requirements.

The Company has not transferred any risk to third-party reinsurers.
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentrations of Credit Risk
Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents, investments, and debt. The Company manages its risk by investing cash equivalents and investment securities in money market instruments and securities of the U.S. government, U.S. government agencies and high-credit-quality issuers of debt securities.
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07 related to improving segment disclosures. This ASU enhances disclosures about significant segment expenses, allows for multiple measures of a segment's profit or loss, and requires additional disclosures about the Chief Operating Decision Maker. The Company adopted ASU 2023-07 for the fiscal year ended December 31, 2024.
In December 2023, the FASB issued ASU 2023-09 which improves and expands upon the income tax disclosures, primarily related to the rate reconciliation and income taxes paid information. The ASU is effective for annual periods beginning after December 15, 2024, including interim periods within that reporting period, with early adoption permitted. As of year-end, the Company is still evaluating the impact on its consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03 which requires that public business entities disclose additional information about specific expense categories in the notes to the financial statements at interim and annual reporting periods. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. As of year-end, the Company is still evaluating the impact on its consolidated financial statements.
v3.25.0.1
Other Investments details (Policies)
 12 Months Ended
Dec. 31, 2024
Other Investments [Abstract]  
Variable Interest Entity Disclosure [Text Block] Investment
The Company has invested $7.0 million in the preferred stock of a variable interest entity, Baystride, Inc., a U.S.-based privately held corporation operating in the pet food industry. The Company does not have power over the activities that most significantly impact the economic performance of the entity and is, therefore, not the primary beneficiary. The Company has the option to purchase all of the outstanding common stock issued by the entity in August 2027 at an amount approximating its expected fair value. The preferred stock investment in the entity is redeemable and, therefore, is accounted for as an available-for-sale debt security and measured at fair value at each balance sheet date — see Note 7.
Additionally, the Company has extended a $7.0 million revolving line of credit to the variable interest entity to fund its inventory purchases, which will increase annually by $2.0 million until the note’s maturity in 2027. Borrowing amounts are subject to limitations based on Baystride’s forecasted revenues and inventory balances. The Company's investment and amounts loaned under the line of credit are recorded in other long-term assets on its consolidated balance sheet. The outstanding loan balance under the line of credit, including accrued interest, was $1.6 million and $4.0 million as of December 31, 2024 and 2023, respectively. The Company has also entered into a series of agreements to provide ancillary services to, and receive reimbursement from, the variable interest entity at cost. The Company provided $0.3 million and $0.4 million of these services for the years ended December 31, 2024 and 2023, respectively.
v3.25.0.1
Fair Value Notes Receivable (Policies)
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Loans, Notes, Trade and Other Receivables Disclosure
The Company's other long-term assets balance also included notes receivable of $4.3 million and $6.8 million as of December 31, 2024 and 2023, respectively, recorded at their estimated recoverable amount. The Company estimates that the carrying value of the notes receivable approximates their fair value. The estimated fair value represents a Level 3 measurement within the fair value hierarchy, and is based on market interest rates and the assessed creditworthiness of the third party.
The Company estimates the fair value of long-term debt based upon rates currently available to the Company for debt with similar terms and remaining maturities. This is a Level 3 measurement. Based upon the terms of the debt, the carrying amount of long-term debt approximated fair value at December 31, 2024.
v3.25.0.1
Segment Reporting (Policies)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting, Policy
The Company has two reporting segments: subscription business and other business. The subscription business segment consists of aggregated operating segments with products that have been created to meet the needs of their distribution channels and have similar target margin profiles. This segment generates revenue primarily from subscription payments related to the Company's direct-to-consumer products. The other business segment generates revenue primarily by underwriting policies on behalf of third parties and has a different margin profile than the Company's subscription business segment. The Company does not undertake marketing efforts for these policies and has a business-to-business relationship with these third-parties.
The Company's chief operating decision maker is our Chief Executive Officer. The chief operating decision maker reviews revenue and operating income (loss) to evaluate segment performance. Revenue, veterinary invoice expense, other cost of revenue, new pet acquisition expenses, and goodwill impairment charges are generally directly attributed to each segment. Other operating expenses, such as technology and development expense, general and administrative expense, and depreciation and amortization, are generally allocated proportionately based on revenue in each segment. Interest and other expenses and income taxes are not allocated to the segments, nor included in the measure of segment profit or loss. The Company does not analyze discrete segment balance sheet information related to long-term assets.
v3.25.0.1
Organization, Consolidation and Presentation of Financial Statements (Tables)
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedules of Concentration of Risk, by Risk Factor For the year ended December 31, 2024, premiums from policies sourced by general agents accounted for 32% of our total revenue, and one general agent sourced members whose premiums accounted for over 10% of our total revenue.
v3.25.0.1
Net Loss per Share (Tables)
 12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
The following potentially dilutive equity securities were not included in the diluted earnings per share of common stock calculation because they would have had an antidilutive effect:
 As of December 31,
 202420232022
Stock options347,334 408,970 629,650 
Restricted stock units970,739 714,382 1,112,552 
v3.25.0.1
Property Plant and Equipment (Tables)
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
Property, equipment, and internal-use software, net consisted of the following (in thousands):
 December 31,
 20242023
Land and improvements$15,911 $15,911 
Building and improvements49,359 48,974 
Software64,368 40,097 
Office equipment and other6,123 6,129 
Construction in progress16,070 34,627 
Property, equipment and internal-use software, at cost151,831 145,738 
Less: Accumulated depreciation(49,640)(42,088)
Property and equipment, net$102,191 $103,650 
v3.25.0.1
Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The following table presents the detail of intangible assets other than goodwill for the periods presented (in thousands):
Gross Carrying ValueAccumulated AmortizationNet Carrying ValueWeighted Average Remaining Useful Life as of December 31, 2024
December 31, 2024:
Licenses$4,773 $— $4,773 N/A
Trade name1,271 (531)740 5.8
Developed technologies16,835 (12,106)4,729 1.4
Customer relationships8,180 (6,394)1,786 1.2
Patents, trademarks, and other2,556 (1,407)1,149 3.0
Total Intangibles$33,615 $(20,438)$13,177 1.6
December 31, 2023:
Licenses$4,773 $— $4,773 
Leases848 (848)— 
Trade name1,294 (412)882 
Developed technologies17,278 (9,023)8,255 
Customer relationships8,379 (4,855)3,524 
Patents, trademarks, and other2,459 (1,148)1,311 
Total Intangibles$35,031 $(16,286)$18,745 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
As of December 31, 2024, expected amortization expense relating to definite-lived intangible assets for each of the next five years and thereafter is as follows (in thousands):
Year ending December 31:
2025$4,423 
20261,370 
20271,272 
2028162 
2029162 
Thereafter277 
Total$7,666 
Schedule of Goodwill Goodwill and Intangible Assets
Goodwill arises from business acquisitions in which the purchase price exceeds the fair value of tangible and intangible assets acquired less assumed liabilities. The carrying values of goodwill and other intangible assets with indefinite lives are reviewed at least annually for possible impairment. The Company may first assess qualitative factors in order to determine if goodwill and indefinite-lived intangible assets are impaired. If through qualitative assessment it is determined that it is more likely than not that goodwill or indefinite-lived assets are not impaired, no further testing is required. If it is determined more likely than not that goodwill or indefinite-lived assets are impaired, the Company’s impairment testing continues with the estimation of reporting unit fair value using a combination of a market approach and an income (discounted cash flow) approach, at the reporting unit level. Estimates of fair value are based on the best information available to the Company as of the assessment date.
The Company has identified reporting units in conjunction with its annual goodwill impairment testing date during the fourth quarter of 2024. All of the Company’s goodwill has been assigned to three separate reporting units within our Subscription Business reportable segment: Trupanion Core – North America, Smart Paws, and PetExpert.
The following is a summary of goodwill by reportable segment for the years ended December 31, 2024 and 2023 (in thousands):
Subscription BusinessOther BusinessTotal
Balance as of January 1, 2023$41,983 $— $41,983 
Effects of foreign currency1,730 — 1,730 
Balance as of December 31, 202343,713 — 43,713 
Impairment charges(5,229)— (5,229)
Effects of foreign currency(1,513)— (1,513)
Balance as of December 31, 2024$36,971 $— $36,971 
v3.25.0.1
Investment Securities Debt and Equity Securities (Tables)
 12 Months Ended
Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Unrealized Gain (Loss) on Investments The amortized cost, gross unrealized holding gains and losses, and estimated fair value of long-term and short-term investments by major security type and class of security were as follows as of December 31, 2024 and 2023 (in thousands):
Amortized
Cost		Gross
Unrealized
Holding
Gains		Gross
Unrealized
Holding
Losses		Fair
Value
As of December 31, 2024
Long-term investments:
Held-to-maturity investments
U.S. treasury securities$373 $— $(1)$372 
$373 $— $(1)$372 
Short-term investments:
Available-for-sale investments
              U.S. treasury securities$70,175 $318 $(202)$70,291 
Mortgage-backed securities and collateralized mortgage obligations12,576 80 (60)12,596 
Other asset-backed securities15,830 134 (8)15,956 
Corporate bonds35,382 284 (43)35,623 
$133,963 $816 $(313)$134,466 
Held-to-maturity investments
U.S. Treasury securities$10,591 $16 $(1)$10,606 
              Certificates of deposit2,032 — — 2,032 
$12,623 $16 $(1)$12,638 
 Amortized
Cost		Gross
Unrealized
Holding
Gains		Gross
Unrealized
Holding
Losses		Fair
Value
As of December 31, 2023
Long-term investments:
Available-for-sale investments
Foreign deposits$11,869 $— $— $11,869 
$11,869 $— $— $11,869 
Held-to-maturity investments
U.S. treasury securities$997 $8 $— $1,005 
$997 $8 $— $1,005 
Short-term investments:
Available-for-sale investments
U.S. treasury securities$44,425 $326 $(64)$44,687 
Mortgage-backed securities and collateralized mortgage obligations10,460 69 (75)10,454 
Other asset-backed securities12,422 67 (53)12,436 
Corporate bonds36,404 332 (123)36,613 
$103,711 $794 $(315)$104,190 
Held-to-maturity investments
U.S. Treasury securities$13,179 $21 $(15)$13,185 
Certificates of deposit12,298 — — 12,298 
$25,477 $21 $(15)$25,483 
Investments Classified by Contractual Maturity Date
Maturities of investments classified as available-for-sale and held-to-maturity were as follows (in thousands):
 December 31, 2024
 Amortized
Cost		Fair
Value
Available-for-sale:
Due under one year$4,178 $4,196 
Due after one year through five years101,379 101,718 
$105,557 $105,914 
Available-for-sale collateralized:
Due under one year$3,823 $3,837 
Due after one year through five years20,691 20,865 
Due after five years through ten years3,614 3,565 
Due after ten years278 285 
$28,406 $28,552 
Held-to-maturity:
Due under one year$12,623 $12,638 
Due after one year through five years373 372 
$12,996 $13,010 
v3.25.0.1
Other Investments (Tables)
 12 Months Ended
Dec. 31, 2024
Other Investments [Abstract]  
Accounts Receivable, Allowance for Credit Loss The following table presents a rollforward of the allowance for credit losses for this investment.
 December 31,
 20242023
Balance at beginning of period$(1,674)$— 
Recovery of (addition to) allowance for credit losses1,674 (1,674)
Balance at end of period$— $(1,674)
v3.25.0.1
Fair Value (Tables)
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Fair value, asset & liabilities measured on recurring basis [Table Text Block]
The following table summarizes, by major security type, the Company's assets that are measured at fair value on a recurring basis, and placement within the fair value hierarchy (in thousands):
 As of December 31, 2024
 Fair ValueLevel 1Level 2Level 3
Assets
Money market funds$91,534 $91,534 $— $— 
Fixed maturities:
Mortgage-backed securities and collateralized mortgage obligations12,596 — 12,596 — 
Other asset-backed securities15,956 — 15,956 — 
Corporate bonds35,623 — 35,623 — 
U.S. Treasury securities70,291 — 70,291 — 
Preferred stock investment7,916 — — 7,916 
Total$233,916 $91,534 $134,466 $7,916 
 As of December 31, 2023
 Fair ValueLevel 1Level 2Level 3
Assets
Money market funds$67,360 $67,360 $— $— 
Fixed maturities:
Mortgage-backed securities and collateralized mortgage obligations10,454 — 10,454 — 
Other asset-backed securities12,436 — 12,436 — 
Corporate bonds36,613 — 36,613 — 
Foreign deposits11,869 11,869 — — 
U.S. Treasury securities44,687 — 44,687 — 
Preferred stock investment5,326 — — 5,326 
Total$188,745 $79,229 $104,190 $5,326 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation The following table presents the change in fair value of the Company’s investment carried at fair value and classified as Level 3 as of December 31, 2024 (in thousands):
 December 31,
 20242023
Balance at beginning of period$5,326 $4,115 
Unrealized gain included in other comprehensive income (loss)916 — 
Reversal of cumulative unrealized loss included in other comprehensive income (loss)— 2,885 
Recovery of (increase in) credit loss included in earnings1,674 (1,674)
Balance at end of period$7,916 $5,326 
v3.25.0.1
Claims Reserve (Tables)
 12 Months Ended
Dec. 31, 2024
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]  
Short-duration Insurance Contracts, Claims Development [Table Text Block]
The following table summarizes the development of veterinary invoice expense, on a constant currency basis, for the Company's subscription business segment by year of occurrence (in thousands, except for cumulative number of veterinary invoices data):
Cumulative veterinary invoice expensesReserve
As of December 31,As of December 31,
Subscription20212022202320242024
Year of Occurrence(unaudited)(unaudited)(unaudited)
2021$348,851 $346,611 $347,130 $347,828 $— 
2022$431,384 $432,694 $433,132 $— 
2023$533,742 $532,630 $1,174 
2024$617,853 $21,910 
$1,931,443 $23,084 

The following table summarizes the development of veterinary invoice expense, on a constant currency basis, for the Company's other business segment by year of occurrence (in thousands, except for cumulative number of veterinary invoices data):
Cumulative veterinary invoice expensesReserve
As of December 31,As of December 31,
Other Business20212022202320242024
Year of Occurrence(unaudited)(unaudited)(unaudited)
2021$129,797 $130,632 $130,559 $130,691 $— 
2022$211,708 $212,147 $211,768 $16 
2023$287,344 $286,241 $1,113 
2024$326,007 $27,422 
$954,707 $28,551 
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block]
The following table summarizes the amounts paid for veterinary invoices, inclusive of related internal processing costs and reported on a constant currency basis, for the subscription segment (in thousands):
Year Ended December 31,
Subscription2021202220232024
Year of Occurrence(unaudited)(unaudited)(unaudited)
2021$329,166 $345,748 $347,130 $347,828 
2022$410,869 $431,371 $433,132 
2023$503,819 $531,456 
2024$595,943 
$1,908,359 
Total amounts unpaid and recorded as a liability$23,084 

The following table summarizes the amounts paid for veterinary invoices, inclusive of related internal processing costs and reported on a constant currency basis, for the other business segment (in thousands):
Year Ended December 31,
Other Business2021202220232024
Year of Occurrence(unaudited)(unaudited)(unaudited)
2021$112,545 $130,139 $130,559 $130,691 
2022$190,010 $211,202 $211,752 
2023$256,600 $285,129 
2024$298,584 
$926,156 
Total amounts unpaid and recorded as a liability$28,551 
v3.25.0.1
Debt (Tables)
 12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Maturities of Long-Term Debt [Table Text Block]
Future principal payments on outstanding borrowings as of December 31, 2024 are as follows (in thousands):
Year Ending December 31,December 31, 2024
20251,350 
20261,350 
202772,113 
202857,125 
Total$131,938 
v3.25.0.1
Stock-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs Stock-based compensation expense recognized in each category of the consolidated statements of operations for the years ended December 31, 2024, 2023 and 2022 was as follows (in thousands):
 Year Ended December 31,
 202420232022
Veterinary invoice expense$3,460 $3,667 $4,145 
Other cost of revenue2,063 1,612 2,339 
Technology and development4,934 2,846 4,742 
General and administrative15,696 17,717 12,831 
New pet acquisition expense7,279 7,319 9,336 
Total expensed stock-based compensation33,432 33,161 33,393 
Capitalized stock-based compensation505 2,135 1,633 
Total stock-based compensation$33,937 $35,296 $35,026 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
Stock Options
The grant date fair value of stock option awards are estimated on the date of grant using the Black-Scholes option-pricing model. The Company did not grant any new stock options during the years ended December 31, 2024, 2023, and 2022.
Schedule of Share-based Compensation, Stock Options, Activity
The following table presents information regarding stock options granted, exercised and forfeited for the periods presented:
Number
of
Options		Weighted Average
Exercise
Price per Share		Aggregate
Intrinsic
Value
(in thousands)
Outstanding as of January 1, 2022807,205 $13.39 $95,765 
Granted— — — 
Exercised(174,721)12.82 10,931 
Forfeited(2,834)18.87 — 
Outstanding as of December 31, 2022629,650 13.53 21,410 
Granted— — — 
Exercised(213,848)12.47 3,720 
Forfeited(6,832)12.80 — 
Outstanding as of December 31, 2023408,970 14.09 6,715 
Granted— — — 
Exercised(61,136)12.91 1,590 
Expired(500)14.93 — 
Outstanding as of December 31, 2024347,334 14.30 11,775 
Exercisable at December 31, 2024347,334 $14.30 $11,775 
As of December 31, 2024, stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 1.7 years.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] The Company has not granted any new stock options since 2017 and all outstanding options vested prior to January 1, 2022.
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity
A summary of the Company’s restricted stock unit activity for the years ended December 31, 2024, 2023 and 2022 is as follows:
Number of 
Shares		Weighted Average
Grant Date Fair Value per
Share
Unvested shares as of January 1, 20221,087,627 $78.94 
Granted623,401 84.11 
Vested(516,077)72.81 
Forfeited(82,399)81.91 
Unvested shares as of December 31, 20221,112,552 84.46 
Granted366,870 26.77 
Vested(669,413)72.52 
Forfeited(95,627)79.60 
Unvested shares as of December 31, 2023714,382 66.64 
Granted957,168 29.21 
Vested(629,217)57.46 
Forfeited(71,594)44.00 
Unvested shares as of December 31, 2024970,739 $37.35 
v3.25.0.1
Comprehensive Income (Loss) (Tables)
 12 Months Ended
Dec. 31, 2024
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Accumulated Comprehensive Income (Loss)
A summary of the components of accumulated other comprehensive income (loss) is as follows (in thousands):
Foreign Currency TranslationNet Unrealized Gain (Loss) on Available-for-Sale SecuritiesTotal
Balance as of January 1, 2022$1,624 $1,453 $3,077 
Other comprehensive income (loss)(4,412)(4,966)(9,378)
Balance as of December 31, 2022$(2,788)$(3,513)$(6,301)
Other comprehensive income (loss)2,712 3,992 6,704 
Balance as of December 31, 2023$(76)$479 $403 
Other comprehensive income (loss)(3,037)22 (3,015)
Balance as of December 31, 2024$(3,113)$501 $(2,612)
v3.25.0.1
Segments (Tables)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Revenue and Gross Profit from Segments [Table Text Block] perating loss of the Company’s segments was as follows (in thousands):
Year Ended December 31,
202420232022
Subscription business:
Revenue$856,521 $712,906 $596,610 
Veterinary invoice expense624,428 543,196 436,880 
Other cost of revenue82,423 70,490 60,804 
Technology and development20,822 13,765 16,555 
General and administrative42,457 36,256 25,964 
New pet acquisition expense71,240 77,172 88,959 
Goodwill impairment charges5,299 — — 
Depreciation and amortization10,970 8,021 7,205 
Subscription business operating loss(1,118)(35,994)(39,757)
Other business:
Revenue429,163 395,699 308,569 
Veterinary invoice expense324,720 287,859 212,857 
Other cost of revenue75,315 76,044 72,453 
Technology and development10,433 7,638 8,578 
General and administrative21,274 23,951 13,415 
New pet acquisition expense139 200 541 
Depreciation and amortization5,496 4,453 3,716 
Other business operating loss(8,214)(4,446)(2,991)
Gain (loss) from investment in joint venture(182)(219)(253)
Total operating loss(9,514)(40,659)(43,001)
Interest expense14,498 12,077 4,267 
Other expense (income), net(14,374)(7,701)(3,072)
Loss before income taxes$(9,638)$(45,035)$(44,196)
Revenue from External Customers by Geographic Areas [Table Text Block]
The following table presents the Company’s revenue by geographic region of the member (in thousands):
 Year Ended December 31,
 202420232022
United States$1,073,150 $935,312 $764,349 
Canada and other212,534 173,293 140,830 
Total revenue$1,285,684 $1,108,605 $905,179 
v3.25.0.1
Dividend Restrictions Statutory Surplus (Tables)
 12 Months Ended
Dec. 31, 2024
Insurance [Abstract]  
Statutory Accounting Practices Disclosure [Table Text Block]
The statutory net income for 2024, 2023 and 2022 and statutory capital and surplus at December 31, 2024, 2023 and 2022, for APIC were as follows (in thousands):
 As of December 31,
 202420232022
Statutory net income$49,007 $40,076 $35,227 
Statutory capital and surplus$245,484 $199,613 $162,232 
v3.25.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Income before Income Tax, Domestic and Foreign
Loss before income taxes was as follows for the years ended December 31, 2024, 2023 and 2022 (in thousands):
 Year Ended December 31,
 202420232022
United States$(758)$(41,019)$(43,794)
Foreign(8,880)(4,016)(402)
Total$(9,638)$(45,035)$(44,196)
Schedule of Components of Income Tax Expense (Benefit)
The components of income tax expense (benefit) were as follows (in thousands):
 Year Ended December 31,
 202420232022
Current:
U.S. federal & state$120 $(8)$82 
Foreign610 464 814 
730 456 896 
Deferred:
U.S. federal & state(48)7 11 
Foreign(687)(805)(431)
(735)(798)(420)
Income tax expense (benefit)$(5)$(342)$476 
Schedule of Effective Income Tax Rate Reconciliation
A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements is presented below:
 Year Ended December 31,    
 202420232022
Federal income taxes at statutory rate21.0 %21.0 %21.0 %
U.S. state income taxes11.1 7.9 3.5 
Equity compensation(28.0)(9.2)2.5 
Change in valuation allowance8.5 (19.1)(26.7)
Other, net(0.4)(0.1)(1.7)
Credits1.2 0.3 0.3 
Goodwill impairment(13.4)— — 
Effective income tax rate— %0.8 %(1.1)%
Schedule of Deferred Tax Assets and Liabilities
The principal components of the Company’s deferred tax assets and liabilities were as follows (in thousands):
 As of December 31,         
 20242023
Deferred tax assets:
Deferred revenue$10,798 $9,988 
Accruals and reserves1,932 2,163 
Net operating loss carryforwards67,128 68,436 
Depreciation and amortization3,387 2,254 
Equity compensation1,323 1,828 
Credits1,297 1,147 
Other977 1,962 
Total deferred tax assets86,842 87,778 
Deferred tax liabilities:
Deferred costs(1,569)(1,537)
Intangible assets(2,302)(3,103)
Other(623)(496)
Total deferred tax liabilities(4,494)(5,136)
Total deferred taxes82,348 82,642 
Less deferred tax asset valuation allowance(84,161)(85,245)
Net deferred tax liability$(1,813)$(2,603)
Schedule of Unrecognized Tax Benefits Roll Forward
A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):
  
Year Ended December 31,
 202420232022
Balance, beginning of year$80 $151 $138 
Increases (decreases) to tax positions related to prior periods3 (72)8 
Increases to tax positions related to the current year— 1 5 
Balance, end of year$83 $80 $151 
v3.25.0.1
SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables)
 12 Months Ended
Dec. 31, 2024
Condensed Financial Information Disclosure [Abstract]  
Condensed Statement of Comprehensive Income
Trupanion, Inc.
Condensed Statements of Operations and Comprehensive Loss
(Parent Company Only, in thousands)
 Year Ended December 31,
 202420232022
Expenses:
Veterinary invoice expense$290 $253 $4,144 
Other cost of revenue347 240 2,340 
Technology and development1,934 1,507 4,930 
General and administrative3,915 5,345 16,346 
New pet acquisition expense1,422 806 9,351 
Depreciation and amortization941 494 289 
Total expenses8,849 8,645 37,400 
Gain (loss) from investment in joint venture192 (237)(192)
Operating loss9,041 (8,882)(37,592)
Interest expense14,345 11,998 4,255 
Other expense (income), net(16,303)(14,442)(8,047)
Loss before income taxes and loss in undistributed earnings of subsidiaries(7,083)(6,438)(33,800)
Income tax benefit18,939 15,766 14,544 
Loss in undistributed earnings of subsidiaries(21,489)(54,021)(25,416)
Net loss$(9,633)$(44,693)$(44,672)
Other comprehensive income (loss), net of taxes:
Other comprehensive income (loss) of subsidiaries(3,015)6,704 (9,378)
Other comprehensive income (loss)(3,015)6,704 (9,378)
Comprehensive loss$(12,648)$(37,989)$(54,050)
Condensed Balance Sheet
Trupanion, Inc.
Condensed Balance Sheets
(Parent Company Only)
(In thousands, except share data)
 December 31,
 20242023
Assets
Current assets:
Cash and cash equivalents$11,951 $10,994 
Accounts and other receivables1,194 1 
Prepaid expenses and other assets815 804 
Total current assets13,960 11,799 
Restricted cash25,406 22,963 
Property and equipment, net4,180 3,981 
Intangible assets, net5,869 5,808 
Other long-term assets12,415 12,540 
Advances to and investments in subsidiaries392,898 377,031 
Total assets$454,728 $434,122 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable, accrued liabilities, and other current liabilities$1,488 $336 
Long-term debt - current portion1,350 1,350 
Total current liabilities2,838 1,686 
Long-term debt127,537 127,580 
Deferred tax liabilities1,057 1,106 
Other liabilities28 28 
Total liabilities131,460 130,400 
Stockholders’ equity:
Common stock: $0.00001 par value per share, 100,000,000 shares authorized; 43,516,631 and 42,888,445 shares issued and outstanding at December 31, 2024; 42,887,052 and 41,858,866 shares issued and outstanding at December 31, 2023
— — 
Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding
— — 
Additional paid-in capital568,302 536,108 
Accumulated other comprehensive income (loss)(2,612)403 
Accumulated deficit(225,888)(216,255)
Treasury stock, at cost: 1,028,186 shares at December 31, 2024 and 2023
(16,534)(16,534)
Total stockholders’ equity323,268 303,722 
Total liabilities and stockholders’ equity$454,728 $434,122 
Condensed Cash Flow Statement
Trupanion, Inc.
Condensed Statements of Cash Flows
(Parent Company Only, in thousands)
 Year Ended December 31,
 202420232022
Operating activities
Net loss$(9,633)$(44,693)$(44,672)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Loss attributable to investments in subsidiaries8,707 39,184 19,331 
Dividends from subsidiaries12,782 14,837 6,942 
Depreciation and amortization941 494 289 
Stock-based compensation expense6,178 4,575 33,393 
Other, net(395)4,200 533 
Changes in operating assets and liabilities507 6,194 (166)
Net cash provided by operating activities19,087 24,791 15,650 
Investing activities
Cash paid in business acquisition, net of cash acquired— — (15,034)
Purchases of property, equipment, and internal-use software(1,201)(172)(516)
Advances to and investments in subsidiaries(13,526)(87,198)(71,671)
Other2,157 1,586 (1,598)
Net cash used in investing activities(12,570)(85,784)(88,819)
Financing activities
Proceeds from debt financing, net of financing fees— 59,972 69,138 
Repayment of debt financing(1,350)(1,225)(487)
Repurchases of common stock— — (5,755)
Proceeds from exercise of stock options752 2,655 2,290 
Shares withheld to satisfy tax withholding(2,519)(1,536)(4,359)
Net cash (used in) provided by financing activities(3,117)59,866 60,827 
Net change in cash, cash equivalents, and restricted cash3,400 (1,127)(12,342)
Cash, cash equivalents, and restricted cash at beginning of period33,957 35,084 47,426 
Cash, cash equivalents, and restricted cash at end of period$37,357 $33,957 $35,084 
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies Narrative (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2024
CAD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2024
USD ($)
Accounting Policies [Abstract]          
Accounts Receivable, Unaffiliated General Agents     $ 249,800,000   $ 252,000,000.0
Deferred Policy Acquisition Costs     7,400,000   7,500,000
Realized Investment Gains (Losses)       $ 0  
Impairment, Amount, License Intangibles     0 0 0
Interest Income, Other   $ 12,400,000 9,000,000.0 3,000,000.0  
Advertising Expense   13,300,000 16,900,000 25,500,000  
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax     (100,000) (2,800,000) (3,100,000)
Premiums Recognized from Fronting Agreement   $ 206,700,000 167,600,000 $ 135,900,000  
Deferred Revenue from Fronting Agreement     9,500,000   11,300,000
Cash Designated for Paying Reinsurance Claims     $ 11,200,000   7,200,000
Reinsurance Trust Minimum Payment $ 2.0        
Reinsurance Trust Payment Unearned Premium Percentage 120.00% 120.00%      
Reinsurance Payment of Percentage of Canadian Claims outstanding 20.00% 20.00%      
Reinsurance Trust Balance $ 19.9        
Reinsurance, Reinsured Risk, Percentage 16.00% 16.00% 15.00% 15.00%  
Accounts Receivable, Allowance for Credit Loss, Writeoff     $ 3,800,000    
Debt Securities, Available-for-Sale, Realized Gain   $ 400,000 300,000    
Debt Securities, Available-for-Sale, Realized Loss   300,000 900,000    
Goodwill and Intangible Asset Impairment     0    
Accounts Receivable, Allowance for Credit Loss     1,700,000    
Concentration Risk [Line Items]          
Goodwill, Impairment Loss   5,299,000 $ 0 $ 0  
Asset Impairment Charges   $ 5,229,000      
Goodwill, Impaired, Accumulated Impairment Loss         $ 5,200,000
Revenue Benchmark [Member] | Product Concentration Risk [Member] | General Agents [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage 32.00% 32.00%      
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies Deferred Acquisition Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Selling and Marketing Expense [Member]      
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]      
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Amortization of Deferred Policy Acquisition Cost $ 6.9 $ 6.0 $ 4.9
Cost of Sales [Member]      
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]      
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Amortization of Deferred Policy Acquisition Cost $ 51.5 $ 45.6 $ 33.9
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies Property, Plant, and Equipment, Useful Life (Details)
Dec. 31, 2024
Land Improvements [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 10 years
Building [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 39 years
Software and Software Development Costs [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 3 years
Software and Software Development Costs [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 5 years
Office Equipment [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 3 years
Office Equipment [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 5 years
v3.25.0.1
Net Loss per Share (Details) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Stock options      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 347,334 408,970 629,650
Restricted stock units      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 970,739 714,382 1,112,552
v3.25.0.1
Business Combinations, Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]      
Cash paid in business acquisition, net of cash acquired $ 0 $ 0 $ 15,034
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 1 year 7 months 6 days    
v3.25.0.1
Property Plant and Equipment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]      
Construction in Progress, Gross $ 16,070 $ 34,627  
Property, Plant and Equipment, Gross 151,831 145,738  
Less: Accumulated depreciation (49,640) (42,088)  
Property and equipment, net 102,191 103,650  
Depreciation expense 11,200 6,700 $ 6,100
Land and Land Improvements [Member]      
Property, Plant and Equipment [Line Items]      
Property, Plant and Equipment, Gross 15,911 15,911  
Building and Building Improvements [Member]      
Property, Plant and Equipment [Line Items]      
Property, Plant and Equipment, Gross 49,359 48,974  
Software      
Property, Plant and Equipment [Line Items]      
Property, Plant and Equipment, Gross 64,368 40,097  
Computer Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Property, Plant and Equipment, Gross $ 6,123 $ 6,129  
v3.25.0.1
Intangible Assets (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]      
Indefinite-Lived License Agreements $ 4,773,000 $ 4,773,000  
Finite-Lived Intangible Asset, Acquired-in-Place Leases   848,000  
Finite-Lived Trade Names, Gross 1,271,000 1,294,000  
Finite-Lived Developed Technologies, Gross 16,835,000 17,278,000  
Finite-Lived Customer Relationships, Gross 8,180,000 8,379,000  
Finite-Lived Patents, Gross 2,556,000 2,459,000  
Intangible Assets, Gross (Excluding Goodwill) 33,615,000 35,031,000  
Finite-Lived Intangible Assets, Accumulated Amortization (20,438,000) (16,286,000)  
Intangible assets, net 13,177,000 18,745,000  
Goodwill 36,971,000 43,713,000 $ 41,983,000
Asset Impairment Charges 5,229,000    
Goodwill, Impairment Loss (5,299,000) 0 0
Goodwill, Foreign Currency Translation Gain (Loss) $ (1,513,000) 1,730,000  
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 1 year 7 months 6 days    
Subscription business [Member]      
Finite-Lived Intangible Assets [Line Items]      
Goodwill $ 36,971,000 43,713,000 41,983,000
Asset Impairment Charges 5,229,000    
Goodwill, Foreign Currency Translation Gain (Loss) (1,513,000) 1,730,000  
Other business      
Finite-Lived Intangible Assets [Line Items]      
Goodwill 0 0 $ 0
Goodwill, Impairment Loss 0    
Goodwill, Foreign Currency Translation Gain (Loss) 0 0  
Leases, Acquired-in-Place [Member]      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Accumulated Amortization   (848,000)  
Intangible assets, net   0  
Trade Names [Member]      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Accumulated Amortization (531,000) (412,000)  
Intangible assets, net $ 740,000 882,000  
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 5 years 9 months 18 days    
Technology-Based Intangible Assets [Member]      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Accumulated Amortization $ (12,106,000) (9,023,000)  
Intangible assets, net $ 4,729,000 8,255,000  
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 1 year 4 months 24 days    
Customer Relationships [Member]      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Accumulated Amortization $ (6,394,000) (4,855,000)  
Intangible assets, net $ 1,786,000 3,524,000  
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 1 year 2 months 12 days    
Patents [Member]      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Accumulated Amortization $ (1,407,000) (1,148,000)  
Intangible assets, net $ 1,149,000 $ 1,311,000  
Patents, trademarks, and other      
Finite-Lived Intangible Assets [Line Items]      
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 3 years    
v3.25.0.1
Intangible Assets, Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]      
Goodwill $ 36,971,000 $ 43,713,000 $ 41,983,000
Goodwill, Foreign Currency Translation Gain (Loss) (1,513,000) 1,730,000  
Indefinite-Lived License Agreements 4,773,000 4,773,000  
Amortization of Intangible Assets $ 5,300,000 $ 5,700,000 $ 4,800,000
v3.25.0.1
Intangible Assets, Expected Amortization (Details)
$ in Thousands
Dec. 31, 2024
USD ($)
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]  
Operating Leases, Future Minimum Payments Receivable, Current $ 4,423
Operating Leases, Future Minimum Payments Receivable, in Two Years 1,370
Operating Leases, Future Minimum Payments Receivable, in Three Years 1,272
Operating Leases, Future Minimum Payments Receivable, in Four Years 162
Operating Leases, Future Minimum Payments Receivable, in Five Years 162
Operating Leases, Future Minimum Payments Receivable, Thereafter 277
Operating Leases, Future Minimum Payments Receivable $ 7,666
v3.25.0.1
Investment Securities (Details) Investment Schedule - AFS - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Schedule of Investments [Line Items]    
Proceeds from Sale of Debt Securities, Available-for-Sale $ 77,100,000 $ 114,700,000
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One 4,178,000  
Available-for-sale securities, due after one year through five years, amortized cost basis 101,379,000  
Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost 105,557,000  
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One 4,196,000  
Available-for-sale securities, due after one year through five years, fair value 101,718,000  
Debt Securities, Available-for-sale 105,914,000  
Other Long-Term Investments    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax   0
Debt Securities, Available-for-Sale, Amortized Cost   11,869,000
Debt Securities, Available-for-Sale, Unrealized Gain   0
Debt Securities, Available-for-sale   11,869,000
Short-Term Investments    
Schedule of Investments [Line Items]    
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain 16,000 21,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss 1,000 15,000
Debt Securities, Held-to-maturity, Fair Value 12,638,000 25,483,000
Debt Securities, Available-for-Sale, Unrealized Gain 816,000 794,000
Debt Securities, Held-to-maturity, Amortized Cost 12,623,000 25,477,000
Collateralized Mortgage-Backed Securities    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale 12,596,000 10,454,000
Collateralized Mortgage-Backed Securities | Short-Term Investments    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (60,000) (75,000)
Debt Securities, Available-for-Sale, Amortized Cost 12,576,000 10,460,000
Debt Securities, Available-for-Sale, Unrealized Gain 80,000 69,000
Debt Securities, Available-for-sale 12,596,000 10,454,000
Asset-Backed Securities    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale 15,956,000 12,436,000
Asset-Backed Securities | Short-Term Investments    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (8,000) (53,000)
Debt Securities, Available-for-Sale, Amortized Cost 15,830,000 12,422,000
Debt Securities, Available-for-Sale, Unrealized Gain 134,000 67,000
Debt Securities, Available-for-sale 15,956,000 12,436,000
Corporate Bond Securities | Short-Term Investments    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (43,000) (123,000)
Debt Securities, Available-for-Sale, Amortized Cost 35,382,000 36,404,000
Debt Securities, Available-for-Sale, Unrealized Gain 284,000 332,000
Debt Securities, Available-for-sale 35,623,000 36,613,000
US Treasury and Government | Other Long-Term Investments    
Schedule of Investments [Line Items]    
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain 0 8,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss 1,000 0
Debt Securities, Held-to-maturity, Fair Value 372,000 1,005,000
US Treasury and Government | Short-Term Investments    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (202,000) (64,000)
Debt Securities, Available-for-Sale, Amortized Cost 70,175,000 44,425,000
Debt Securities, Available-for-Sale, Unrealized Gain 318,000 326,000
Debt Securities, Available-for-sale 70,291,000 44,687,000
Total Short-Term Available-for-Sale [Domain] | Short-Term Investments    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (313,000) (315,000)
Debt Securities, Available-for-Sale, Amortized Cost 133,963,000 103,711,000
Debt Securities, Available-for-sale 134,466,000 104,190,000
Deposits [Member]    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale   11,869,000
Deposits [Member] | Other Long-Term Investments    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax   0
Debt Securities, Available-for-Sale, Amortized Cost   11,869,000
Debt Securities, Available-for-Sale, Unrealized Gain   0
Debt Securities, Available-for-sale   11,869,000
Total Long-Term Held-to-Maturity | Other Long-Term Investments    
Schedule of Investments [Line Items]    
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain 0  
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss 1,000 0
Debt Securities, Held-to-maturity, Fair Value 372,000 1,005,000
Debt Securities, Held-to-maturity, Amortized Cost 373,000 997,000
US Treasury Securities [Member] | Short-Term Investments    
Schedule of Investments [Line Items]    
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain 16,000 21,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss 1,000 15,000
Debt Securities, Held-to-maturity, Fair Value 10,606,000 13,185,000
Certificates of Deposit [Member] | Short-Term Investments    
Schedule of Investments [Line Items]    
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain 0 0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss 0 0
Debt Securities, Held-to-maturity, Fair Value 2,032,000 12,298,000
Debt Securities, Held-to-maturity, Amortized Cost $ 2,032,000 $ 12,298,000
v3.25.0.1
Investment Securities (Details) - Investment Schedule - HTM - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Short-Term Investments    
Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One $ 12,623,000  
Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five 373,000  
Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date 12,996,000  
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One 12,638,000  
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five 372,000  
Debt Securities, Held-to-Maturity, Maturity, Allocated and Single Maturity Date, Fair Value 13,010,000  
Debt Securities, Available-for-sale 105,914,000  
Other Long-Term Investments    
Short-Term Investments    
Debt Securities, Available-for-sale   $ 11,869,000
Short-Term Investments    
Short-Term Investments    
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain 16,000 21,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss (1,000) (15,000)
Debt Securities, Held-to-maturity, Fair Value 12,638,000 25,483,000
US Treasury and Government | Other Long-Term Investments    
Short-Term Investments    
Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss 373,000 997,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain 0 8,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss (1,000) 0
Debt Securities, Held-to-maturity, Fair Value 372,000 1,005,000
US Treasury and Government | Short-Term Investments    
Short-Term Investments    
Debt Securities, Available-for-sale 70,291,000 44,687,000
US Treasury Securities [Member] | Short-Term Investments    
Short-Term Investments    
Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss 10,591,000 13,179,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain 16,000 21,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss (1,000) (15,000)
Debt Securities, Held-to-maturity, Fair Value $ 10,606,000 $ 13,185,000
v3.25.0.1
Other Investments (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2024
AUD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Other Investments [Abstract]          
Purchase of Equity Interest         $ 7,000,000.0
Increase (Decrease) in Notes Receivables $ 7,000,000.0        
Line of Credit outstanding balance, Variable Interest Entity 1,600,000 $ 4,000,000.0      
Services performed for Variable Interest Entity 300,000 400,000      
Financing Receivable, Revolving, Annual Increase 2,000,000.0        
Other Commitment     $ 2.2    
Payments to Acquire Interest in Joint Venture 1,500,000        
Debt Securities, Available-for-Sale, Allowance for Credit Loss [Line Items]          
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 1,674,000 (1,674,000)      
Accounts Receivable, Allowance for Credit Loss   1,700,000      
Preferred Stock          
Debt Securities, Available-for-Sale, Allowance for Credit Loss [Line Items]          
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 1,674,000 (1,674,000)      
Accounts Receivable, Allowance for Credit Loss $ 0 $ (1,674,000)   $ 0  
v3.25.0.1
Fair Value (Details) Unobservable - USD ($)
Dec. 31, 2024
Jan. 01, 2024
Dec. 31, 2023
Jan. 01, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Noncontrolling Interest in Variable Interest Entity $ 7,916,000   $ 5,326,000  
Assets, Fair Value Disclosure 233,916,000   188,745,000  
Fair Value, Inputs, Level 1 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Noncontrolling Interest in Variable Interest Entity 0   0  
Assets, Fair Value Disclosure 91,534,000   79,229,000  
Fair Value, Inputs, Level 2 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Noncontrolling Interest in Variable Interest Entity 0   0  
Assets, Fair Value Disclosure 134,466,000   104,190,000  
Fair Value, Inputs, Level 3 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Noncontrolling Interest in Variable Interest Entity 7,916,000 $ 5,326,000 5,326,000 $ 4,115,000
Assets, Fair Value Disclosure 7,916,000   5,326,000  
Money Market Funds [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Cash and Cash Equivalents, Fair Value Disclosure 91,534,000   67,360,000  
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Cash and Cash Equivalents, Fair Value Disclosure 91,534,000   67,360,000  
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Cash and Cash Equivalents, Fair Value Disclosure 0   0  
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Cash and Cash Equivalents, Fair Value Disclosure $ 0   $ 0  
v3.25.0.1
Fair Value (Details) Unobservable - Credit Loss Rollforward - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Jan. 01, 2024
Jan. 01, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Noncontrolling Interest in Variable Interest Entity $ 7,916,000 $ 5,326,000    
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax 916,000 0    
Assets, Fair Value Adjustment 0 2,885,000    
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 1,674,000 (1,674,000)    
Fair Value, Inputs, Level 3 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Noncontrolling Interest in Variable Interest Entity $ 7,916,000 $ 5,326,000 $ 5,326,000 $ 4,115,000
v3.25.0.1
Fair Value Narrative (Details) - USD ($)
Dec. 31, 2024
Jan. 01, 2024
Dec. 31, 2023
Jan. 01, 2023
Fair Value Disclosures [Abstract]        
Noncontrolling Interest in Variable Interest Entity $ 7,916,000   $ 5,326,000  
Notes Receivable, Fair Value Disclosure 4,300,000   6,800,000  
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Noncontrolling Interest in Variable Interest Entity 7,916,000   5,326,000  
Debt Securities, Available-for-sale 105,914,000      
Fair Value, Inputs, Level 3 [Member]        
Fair Value Disclosures [Abstract]        
Noncontrolling Interest in Variable Interest Entity 7,916,000 $ 5,326,000 5,326,000 $ 4,115,000
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Noncontrolling Interest in Variable Interest Entity 7,916,000 $ 5,326,000 5,326,000 $ 4,115,000
Fair Value, Inputs, Level 1 [Member]        
Fair Value Disclosures [Abstract]        
Noncontrolling Interest in Variable Interest Entity 0   0  
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Noncontrolling Interest in Variable Interest Entity 0   0  
Fair Value, Inputs, Level 2 [Member]        
Fair Value Disclosures [Abstract]        
Noncontrolling Interest in Variable Interest Entity 0   0  
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Noncontrolling Interest in Variable Interest Entity 0   0  
Collateralized Mortgage-Backed Securities        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 12,596,000   10,454,000  
Collateralized Mortgage-Backed Securities | Fair Value, Inputs, Level 3 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 0   0  
Collateralized Mortgage-Backed Securities | Fair Value, Inputs, Level 1 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 0   0  
Collateralized Mortgage-Backed Securities | Fair Value, Inputs, Level 2 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 12,596,000   10,454,000  
Asset-Backed Securities        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 15,956,000   12,436,000  
Asset-Backed Securities | Fair Value, Inputs, Level 3 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 0   0  
Asset-Backed Securities | Fair Value, Inputs, Level 1 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 0   0  
Asset-Backed Securities | Fair Value, Inputs, Level 2 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 15,956,000   12,436,000  
Total Corporate Bond Securities Member LT and ST [Domain]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 35,623,000   36,613,000  
Total Corporate Bond Securities Member LT and ST [Domain] | Fair Value, Inputs, Level 3 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 0   0  
Total Corporate Bond Securities Member LT and ST [Domain] | Fair Value, Inputs, Level 1 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 0   0  
Total Corporate Bond Securities Member LT and ST [Domain] | Fair Value, Inputs, Level 2 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 35,623,000   36,613,000  
Deposits [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale     11,869,000  
Deposits [Member] | Fair Value, Inputs, Level 3 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale     0  
Deposits [Member] | Fair Value, Inputs, Level 1 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale     11,869,000  
Deposits [Member] | Fair Value, Inputs, Level 2 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale     0  
Total US Treasury LT and ST Member [Domain]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 70,291,000   44,687,000  
Total US Treasury LT and ST Member [Domain] | Fair Value, Inputs, Level 3 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 0   0  
Total US Treasury LT and ST Member [Domain] | Fair Value, Inputs, Level 1 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 0   0  
Total US Treasury LT and ST Member [Domain] | Fair Value, Inputs, Level 2 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Debt Securities, Available-for-sale 70,291,000   44,687,000  
Money Market Funds [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Cash and Cash Equivalents, Fair Value Disclosure 91,534,000   67,360,000  
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Cash and Cash Equivalents, Fair Value Disclosure 0   0  
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Cash and Cash Equivalents, Fair Value Disclosure 91,534,000   67,360,000  
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]        
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]        
Cash and Cash Equivalents, Fair Value Disclosure $ 0   $ 0  
v3.25.0.1
Claims Reserve (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Subscription business [Member]      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Claims reserve at beginning of year $ 31,548,000 $ 21,543,000 $ 22,407,000
Current Year Claims and Claims Adjustment Expense 623,928,000 540,396,000 439,679,000
Prior Year Claims and Claims Adjustment Expense   (2,800,000) (2,799,000)
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims 624,428,000 543,196,000 436,880,000
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year 598,593,000 506,294,000 414,778,000
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years 30,875,000 23,001,000 18,739,000
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid 629,468,000 529,295,000 433,517,000
Claims expense non-cash 3,424,000 3,896,000 4,227,000
Claims reserve at end of year 23,084,000 31,548,000 21,543,000
Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net, Not Separately Presented 500,000 1,200,000 1,700,000
Other Operating Segment [Member]      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Claims reserve at beginning of year 31,690,000 22,191,000 17,264,000
Current Year Claims and Claims Adjustment Expense 326,018,000 287,361,000 211,729,000
Prior Year Claims and Claims Adjustment Expense (1,298,000) (498,000) (1,128,000)
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims 324,720,000 287,859,000 212,857,000
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year 298,596,000 256,616,000 190,031,000
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years 29,263,000 21,744,000 17,899,000
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid 327,859,000 278,360,000 207,930,000
Claims expense non-cash 0 0 0
Claims reserve at end of year 28,551,000 31,690,000 22,191,000
Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net, Not Separately Presented $ (1,300,000)    
Other business      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net, Not Separately Presented   $ 1,100,000 $ 200,000
v3.25.0.1
Claims Reserve Cumulative claims paid and claims adjustment expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Subscription business [Member]        
Claims Development [Line Items]        
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net $ 1,931,443      
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 23,084      
Subscription business [Member] | Short-duration Insurance Contracts, Accident Year 2018 [Member]        
Claims Development [Line Items]        
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net 347,828 $ 347,130 $ 346,611 $ 348,851
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 0      
Subscription business [Member] | Short-Duration Insurance Contract, Accident Year 2019        
Claims Development [Line Items]        
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net 433,132 432,694 431,384  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 0      
Subscription business [Member] | Short-Duration Insurance Contract, Accident Year 2020        
Claims Development [Line Items]        
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net 532,630 533,742    
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 1,174      
Subscription business [Member] | Short-Duration Insurance Contract, Accident Year 2021        
Claims Development [Line Items]        
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net 617,853      
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 21,910      
Other Operating Segment [Member]        
Claims Development [Line Items]        
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net 954,707      
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 28,551      
Other Operating Segment [Member] | Short-duration Insurance Contracts, Accident Year 2018 [Member]        
Claims Development [Line Items]        
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net 130,691 130,559 130,632 $ 129,797
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 0      
Other Operating Segment [Member] | Short-Duration Insurance Contract, Accident Year 2019        
Claims Development [Line Items]        
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net 211,768 212,147 $ 211,708  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 16      
Other Operating Segment [Member] | Short-Duration Insurance Contract, Accident Year 2020        
Claims Development [Line Items]        
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net 286,241 $ 287,344    
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 1,113      
Other Operating Segment [Member] | Short-Duration Insurance Contract, Accident Year 2021        
Claims Development [Line Items]        
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net 326,007      
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net $ 27,422      
v3.25.0.1
Claims Reserve Incurred claims and claim adjustment expense (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Subscription business [Member]        
Liability for Claims and Claims Adjustment Expense [Line Items]        
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net $ 1,908,359      
Liability for Unpaid Claims and Claims Adjustment Expense, Net 23,084 $ 31,548 $ 21,543 $ 22,407
Subscription business [Member] | Short-duration Insurance Contracts, Accident Year 2018 [Member]        
Liability for Claims and Claims Adjustment Expense [Line Items]        
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net 347,828 347,130 345,748 329,166
Subscription business [Member] | Short-Duration Insurance Contract, Accident Year 2019        
Liability for Claims and Claims Adjustment Expense [Line Items]        
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net 433,132 431,371 410,869  
Subscription business [Member] | Short-Duration Insurance Contract, Accident Year 2020        
Liability for Claims and Claims Adjustment Expense [Line Items]        
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net 531,456 503,819    
Subscription business [Member] | Short-Duration Insurance Contract, Accident Year 2021        
Liability for Claims and Claims Adjustment Expense [Line Items]        
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net 595,943      
Other Operating Segment [Member]        
Liability for Claims and Claims Adjustment Expense [Line Items]        
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net 926,156      
Liability for Unpaid Claims and Claims Adjustment Expense, Net 28,551 31,690 22,191 17,264
Other Operating Segment [Member] | Short-duration Insurance Contracts, Accident Year 2018 [Member]        
Liability for Claims and Claims Adjustment Expense [Line Items]        
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net 130,691 130,559 130,139 $ 112,545
Other Operating Segment [Member] | Short-Duration Insurance Contract, Accident Year 2019        
Liability for Claims and Claims Adjustment Expense [Line Items]        
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net 211,752 211,202 $ 190,010  
Other Operating Segment [Member] | Short-Duration Insurance Contract, Accident Year 2020        
Liability for Claims and Claims Adjustment Expense [Line Items]        
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net 285,129 $ 256,600    
Other Operating Segment [Member] | Short-Duration Insurance Contract, Accident Year 2021        
Liability for Claims and Claims Adjustment Expense [Line Items]        
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net $ 298,584      
v3.25.0.1
Debt (Details) - Narrative - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Sep. 21, 2023
Feb. 16, 2023
Dec. 29, 2022
Line of Credit Facility [Line Items]          
Line of Credit Facility, Expiration Date Mar. 25, 2027        
Long-Term Debt $ 127,537,000 $ 127,580,000      
Line of Credit Facility, Initiation Date Mar. 25, 2022        
Line of credit facility, maximum borrowing capacity $ 150,000,000.0        
Debt Instrument, Interest Rate, Stated Percentage 9.50%        
Debt Issuance Costs, Gross $ 5,900,000        
Line of Credit Facility, Periodic Payment, Principal Percentage 0.25%        
Initial Loan          
Line of Credit Facility [Line Items]          
Long-Term Debt $ 60,000,000.0        
Delayed Draw Term Loan          
Line of Credit Facility [Line Items]          
Long-Term Debt     $ 25,000,000.0 $ 35,000,000.0 $ 15,000,000.0
Unfunded Loan Commitment          
Line of Credit Facility [Line Items]          
Line of Credit Facility, Remaining Borrowing Capacity $ 75,000,000.0        
Line of Credit, Date of Last Availability Sep. 25, 2023        
Line of Credit Facility, Expiration Date Mar. 25, 2028        
Revolving Credit Facility          
Line of Credit Facility [Line Items]          
Line of Credit Facility, Remaining Borrowing Capacity $ 15,000,000.0        
Line of Credit, Date of Last Availability Mar. 25, 2027        
Line of Credit Facility, Expiration Date Mar. 25, 2027        
v3.25.0.1
Debt (Details) - Schedule of Maturities
$ in Thousands
Dec. 31, 2024
USD ($)
Debt Disclosure [Abstract]  
Long-Term Debt, Maturity, Year One $ 1,350
Long-Term Debt, Maturity, Year Two 1,350
Long-Term Debt, Maturity, Year Three 72,113
Long-Term Debt, Maturity, Year Four 57,125
Long-term Line of Credit $ 131,938
v3.25.0.1
Stock-based Compensation Expense Category (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Stock-based Compensation      
Share-based Compensation Arrangement by Share-based Payment Award, Capitalized Cost $ 505 $ 2,135 $ 1,633
Total stock-based compensation 33,937 35,296 35,026
Claims expenses      
Stock-based Compensation      
Total stock-based compensation 3,460 3,667 4,145
Other cost of revenue      
Stock-based Compensation      
Total stock-based compensation 2,063 1,612 2,339
Technology and development      
Stock-based Compensation      
Total stock-based compensation 4,934 2,846 4,742
General and administrative      
Stock-based Compensation      
Total stock-based compensation 15,696 17,717 12,831
Sales and marketing      
Stock-based Compensation      
Total stock-based compensation 7,279 7,319 9,336
Total Expense [Member]      
Stock-based Compensation      
Total stock-based compensation $ 33,432 $ 33,161 $ 33,393
v3.25.0.1
Stock-based Compensation (Details) Narrative
 12 Months Ended
Dec. 31, 2024
USD ($)
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Options outstanding, weighted average remaining contractual term 1 year 8 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term 1 year 8 months 12 days
Share-Based Payment Arrangement, Accelerated Cost $ 4,800,000
Restricted stock units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Restricted stock, outstanding | shares 970,739
Compensation cost not yet recognized $ 34,300,000
Weighted average remaining vesting period 2 years 2 months 12 days
v3.25.0.1
Stock-based Compensation Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Number of Options        
Beginning balance 408,970 629,650 807,205  
Granted 0 0 0  
Exercised 61,136 213,848 174,721  
Forfeited 500 6,832 2,834  
Ending Balance 347,334 408,970 629,650  
Exercisable at December 31, 2024 347,334      
Weighted Average Exercise Price per Share        
Beginning Balance (usd per share) $ 14.09 $ 13.53 $ 13.39  
Granted (usd per share) 0 0 0  
Exercised (usd per share) 12.91 12.47 12.82  
Forfeited (usd per share) 14.93 12.80 18.87  
Ending Balance (usd per share) 14.30 $ 14.09 $ 13.53  
Vested and exercisable at December 31, 2014 (usd per share) $ 14.30      
Aggregate Intrinsic Value (in thousands)        
Outstanding $ 11,775 $ 6,715 $ 21,410 $ 95,765
Exercised 1,590 $ 3,720 $ 10,931  
Exercisable at December 31, 2024 $ 11,775      
v3.25.0.1
Stock-based Compensation Restricted Stock Awards (Details) - Restricted Stock - $ / shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Beginning balance 714,382 1,112,552 1,087,627
Granted 957,168 366,870 623,401
Vested (629,217) (669,413) (516,077)
Forfeited (71,594) (95,627) (82,399)
Ending balance 970,739 714,382 1,112,552
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Roll Forward]      
Beginning balance (usd per share) $ 66.64 $ 84.46 $ 78.94
Restricted stock awards granted (usd per share) 29.21 26.77 84.11
Awards upon which restrictions lapsed (usd per share) 57.46 72.52 72.81
Restricted stock awards forfeited (usd per share) 44.00 79.60 81.91
Ending balance (usd per share) $ 37.35 $ 66.64 $ 84.46
v3.25.0.1
Stockholder's Equity Narrative (Details) - shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Class of Stock Disclosures [Abstract]    
Common Stock, Shares Authorized 100,000,000 100,000,000
Common Stock, Shares, Outstanding 42,488,445 41,858,866
Preferred Stock, Shares Authorized 10,000,000 10,000,000
Treasury Stock, Shares, Acquired 0  
v3.25.0.1
Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Stockholders' Equity Attributable to Parent $ 323,268 $ 303,722 $ 305,297 $ 332,200
Other comprehensive income (loss) (3,015) 6,704 (9,378)  
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax 22 3,992 (4,966)  
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax (3,037) 2,712 (4,412)  
Accumulated Foreign Currency Adjustment Attributable to Parent        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Stockholders' Equity Attributable to Parent (3,113) (76) (2,788) 1,624
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax (3,037) 2,712 (4,412)  
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Stockholders' Equity Attributable to Parent 501 479 (3,513) 1,453
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax 22 3,992 (4,966)  
Accumulated Other Comprehensive Income (Loss)        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Stockholders' Equity Attributable to Parent (2,612) 403 (6,301) $ 3,077
Other comprehensive income (loss) $ (3,015) $ 6,704 $ (9,378)  
v3.25.0.1
Segments (Details) Business Segment - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Revenue $ 1,285,684,000 $ 1,108,605,000 $ 905,179,000
Veterinary invoice expense 949,148,000 831,055,000 649,737,000
Other cost of revenue 157,738,000 146,534,000 133,257,000
Technology and development 31,255,000 21,403,000 25,133,000
General and administrative 63,731,000 60,207,000 39,379,000
New pet acquisition expense 71,379,000 77,372,000 89,500,000
Goodwill, Impairment Loss 5,299,000 0 0
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest (9,638,000) (45,035,000) (44,196,000)
Gain (loss) from investment in joint venture (182,000) (219,000) (253,000)
Operating loss (9,514,000) (40,659,000) (43,001,000)
Interest expense 14,498,000 12,077,000 4,267,000
Other expense (income), net (14,374,000) (7,701,000) (3,072,000)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (9,638,000) (45,035,000) (44,196,000)
Subscription business      
Segment Reporting Information [Line Items]      
Revenue 856,521,000 712,906,000 596,610,000
Veterinary invoice expense 624,428,000 543,196,000 436,880,000
Other cost of revenue 82,423,000 70,490,000 60,804,000
Technology and development 20,822,000 13,765,000 16,555,000
General and administrative 42,457,000 36,256,000 25,964,000
New pet acquisition expense 71,240,000 77,172,000 88,959,000
Depreciation and amortization 10,970,000 8,021,000 7,205,000
Operating loss (1,118,000) (35,994,000) (39,757,000)
Other business      
Segment Reporting Information [Line Items]      
Revenue 429,163,000 395,699,000 308,569,000
Veterinary invoice expense 324,720,000 287,859,000 212,857,000
Other cost of revenue 75,315,000 76,044,000 72,453,000
Technology and development 10,433,000 7,638,000 8,578,000
General and administrative 21,274,000 23,951,000 13,415,000
New pet acquisition expense 139,000 200,000 541,000
Depreciation and amortization 5,496,000 4,453,000 3,716,000
Operating loss (8,214,000) $ (4,446,000) $ (2,991,000)
Other business      
Segment Reporting Information [Line Items]      
Goodwill, Impairment Loss $ 0    
v3.25.0.1
Segments (Details) Revenue by Geography - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Revenues $ 1,285,684 $ 1,108,605 $ 905,179
United States      
Segment Reporting Information [Line Items]      
Revenues 1,073,150 935,312 764,349
Canada and other      
Segment Reporting Information [Line Items]      
Revenues $ 212,534 $ 173,293 $ 140,830
v3.25.0.1
Dividend Restrictions Statutory Surplus (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statutory Accounting Practices [Line Items]      
Dividends from subsidiaries $ 12,800,000 $ 14,900,000 $ 6,900,000
Statutory Accounting Practices, Statutory Capital and Surplus, Balance 7,000,000.0    
Deposit Assets 11,500,000    
American Pet Insurance Company (APIC) [Member]      
Statutory Accounting Practices [Line Items]      
Dividends from subsidiaries 4,200,000 7,600,000  
Statutory Accounting Practices, Statutory Net Income Amount 49,007,000 40,076,000 35,227,000
Statutory Accounting Practices, Statutory Capital and Surplus, Balance 245,484,000 199,613,000 $ 162,232,000
Statutory Accounting Practices, Statutory Capital and Surplus Required 105,300,000    
Statutory Accounting Practices, Statutory Capital Funding 1,100,000 3,800,000  
Wyndham Insurance Company (SAC) Limited [Member]      
Statutory Accounting Practices [Line Items]      
Dividends from subsidiaries 8,600,000 7,300,000  
ZPIC Insurance Company (ZPIC) [Member]      
Statutory Accounting Practices [Line Items]      
Statutory Accounting Practices, Statutory Capital Funding $ 200,000 200,000  
GPIC Insurance Company (ZPIC) Member      
Statutory Accounting Practices [Line Items]      
Statutory Accounting Practices, Statutory Capital Funding   $ 8,500,000  
v3.25.0.1
Income Taxes Income before taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
United States $ (758) $ (41,019) $ (43,794)
Foreign (8,880) (4,016) (402)
Loss before income taxes $ (9,638) $ (45,035) $ (44,196)
v3.25.0.1
Income Taxes Income tax benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
U.S. federal & state $ 120 $ (8) $ 82
Foreign 610 464 814
Current income tax expense (benefit) 730 456 896
U.S. federal & state (48) 7 11
Foreign (687) (805) (431)
Deferred Income Tax Expense (Benefit) (735) (798) (420)
Income tax (benefit) expense $ (5) $ (342) $ 476
v3.25.0.1
Income Taxes Tax Rate Reconciliation (Details)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 21.00% 21.00% 21.00%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, US State Income Taxes, Percent 11.10% 7.90% 3.50%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent (28.00%) (9.20%) (2.50%)
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 8.50% (19.10%) (26.70%)
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent (0.40%) (0.10%) (1.70%)
Effective Income Tax Rate Reconciliation, Tax Credit, Percent 1.20% 0.30% 0.30%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent (13.40%) 0.00% 0.00%
Effective income tax rate 0.00% 0.80% (1.10%)
v3.25.0.1
Income Taxes Deferred tax assets and liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Deferred tax assets:    
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Unearned Premiums Reserve $ 10,798 $ 9,988
Accruals and reserves 1,932 2,163
Net operating loss carryforwards 67,128 68,436
Depreciation and amortization 3,387 2,254
Equity compensation 1,323 1,828
Credits 1,297 1,147
Other 977 1,962
Total deferred tax assets 86,842 87,778
Deferred tax liabilities:    
Deferred costs (1,569) (1,537)
Intangible assets (2,302) (3,103)
Other (623) (496)
Total deferred tax liabilities (4,494) (5,136)
Deferred Tax Assets, Net 82,348 82,642
Less deferred tax asset valuation allowance (84,161) (85,245)
Net deferred tax liability $ (1,813) $ (2,603)
v3.25.0.1
Income Taxes Narrative (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Income Tax Disclosure [Abstract]  
Operating loss carryforwards $ 67.1
Deferred Income Taxes and Tax Credits 1.3
Operating Loss Carryforwards, Limitations on Use, Value 0.3
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount $ 1.1
v3.25.0.1
Income Taxes Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Unrecognized Tax Benefits [Roll Forward]      
Balance, beginning of year $ 80 $ 151 $ 138
Increases (decreases) to tax positions related to prior periods (3) (72) (8)
Increases to tax positions related to the current year 0 1 5
Balance, end of year $ 83 $ 80 $ 151
v3.25.0.1
Retirement Plan Details (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Retirement Benefits [Abstract]      
Defined Contribution Plan, Employer Discretionary Contribution Amount $ 0.0 $ 0.0 $ 0.0
v3.25.0.1
Schedule 1-Parent Only Disclosures Condensed Statements of Operations and Comprehensive Loss (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Condensed Financial Statements, Captions [Line Items]      
Revenue $ 1,285,684,000 $ 1,108,605,000 $ 905,179,000
Technology and development 31,255,000 21,403,000 25,133,000
General and administrative 63,731,000 60,207,000 39,379,000
New pet acquisition expense 71,379,000 77,372,000 89,500,000
Gain (loss) from investment in joint venture (182,000) (219,000) (253,000)
Operating loss (9,514,000) (40,659,000) (43,001,000)
Interest expense 14,498,000 12,077,000 4,267,000
Other expense (income), net 14,374,000 7,701,000 3,072,000
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total $ (12,648,000) $ (37,989,000) $ (54,050,000)
Effective Income Tax Rate Reconciliation, Tax Credit, Percent 1.20% 0.30% 0.30%
Parent Company      
Condensed Financial Statements, Captions [Line Items]      
Veterinary invoice expense $ 290,000 $ 253,000 $ 4,144,000
Other costs of revenue 347,000 240,000 2,340,000
Technology and development 1,934,000 1,507,000 4,930,000
General and administrative 3,915,000 5,345,000 16,346,000
New pet acquisition expense 1,422,000 806,000 9,351,000
Depreciation and amortization 941,000 494,000 289,000
Total expenses 8,849,000 8,645,000 37,400,000
Gain (loss) from investment in joint venture 192,000 (237,000) (192,000)
Operating loss 9,041,000 (8,882,000) (37,592,000)
Interest expense 14,345,000 11,998,000 4,255,000
Other expense (income), net 16,303,000 14,442,000 8,047,000
Loss before equity in undistributed earnings of subsidiaries (7,083,000) (6,438,000) (33,800,000)
Income tax benefit 18,939,000 15,766,000 14,544,000
Loss in undistributed earnings of subsidiaries (21,489,000) (54,021,000) (25,416,000)
Net loss (9,633,000) (44,693,000) (44,672,000)
Other comprehensive income (loss) of subsidiaries (3,015,000) 6,704,000 (9,378,000)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total $ (12,648,000) $ (37,989,000) $ (54,050,000)
v3.25.0.1
Schedule 1-Parent Only Disclosures Condensed Balance Sheet (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Assets [Abstract]        
Cash and cash equivalents $ 160,295,000 $ 147,501,000    
Accounts and other receivables 274,031,000 267,899,000    
Prepaid expenses and other assets 15,912,000 17,022,000    
Total current assets 597,327,000 562,089,000    
Restricted cash 39,235,000 22,963,000    
Property, equipment, and internal-use software, net 102,191,000 103,650,000    
Intangible assets, net 13,177,000 18,745,000    
Other long-term assets 17,579,000 18,922,000    
Total assets 806,853,000 782,948,000    
Liabilities and Equity [Abstract]        
Long-Term Debt, Current Maturities 1,350,000 1,350,000    
Total current liabilities 349,626,000 344,474,000    
Long-Term Debt 127,537,000 127,580,000    
Deferred tax liabilities 1,946,000 2,685,000    
Other liabilities 4,476,000 4,487,000    
Total liabilities 483,585,000 479,226,000    
Common stock: $0.00001 par value per share 0 0    
Preferred stock: $0.00001 par value per share 0 0    
Additional paid-in capital 568,302,000 536,108,000    
Accumulated other comprehensive income (loss) (2,612,000) 403,000    
Accumulated deficit (225,888,000) (216,255,000)    
Treasury stock, at cost (16,534,000) (16,534,000)    
Total stockholders' equity 323,268,000 303,722,000 $ 305,297,000 $ 332,200,000
Total liabilities and stockholders’ equity $ 806,853,000 $ 782,948,000    
Common Stock, Shares Authorized 100,000,000 100,000,000    
Common Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001    
Preferred Stock, Shares Issued 0 0    
Preferred Stock, Shares Authorized 10,000,000 10,000,000    
Preferred Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001    
Treasury Stock, Common, Shares 1,028,186 1,028,186    
Parent Company        
Assets [Abstract]        
Cash and cash equivalents $ 11,951,000 $ 10,994,000    
Accounts and other receivables 1,194,000 1,000    
Prepaid expenses and other assets 815,000 804,000    
Total current assets 13,960,000 11,799,000    
Restricted cash 25,406,000 22,963,000    
Property, equipment, and internal-use software, net 4,180,000 3,981,000    
Intangible assets, net 5,869,000 5,808,000    
Other long-term assets 12,415,000 12,540,000    
Advances to and investments in subsidiaries 392,898,000 377,031,000    
Total assets 454,728,000 434,122,000    
Liabilities and Equity [Abstract]        
Accounts payable, accrued liabilities, and other current liabilities 1,488,000 336,000    
Long-Term Debt, Current Maturities 1,350,000 1,350,000    
Total current liabilities 2,838,000 1,686,000    
Long-Term Debt 127,537,000 127,580,000    
Deferred tax liabilities 1,057,000 1,106,000    
Other liabilities 28,000 28,000    
Total liabilities 131,460,000 130,400,000    
Common stock: $0.00001 par value per share 0 0    
Preferred stock: $0.00001 par value per share 0 0    
Additional paid-in capital 568,302,000 536,108,000    
Accumulated other comprehensive income (loss) (2,612,000) 403,000    
Accumulated deficit (225,888,000) (216,255,000)    
Treasury stock, at cost (16,534,000) (16,534,000)    
Total stockholders' equity 323,268,000 303,722,000    
Total liabilities and stockholders’ equity $ 454,728,000 $ 434,122,000    
Common Stock, Shares Authorized 100,000,000 100,000,000    
Common Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001    
Preferred Stock, Shares Outstanding 0 0    
Preferred Stock, Shares Issued 0 0    
Preferred Stock, Shares Authorized 10,000,000 10,000,000    
Preferred Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001    
Treasury Stock, Common, Shares   1,028,186    
v3.25.0.1
Parent-Only Condensed Consolidated Balance Sheet Parentheticals (Details) - $ / shares
Dec. 31, 2024
Dec. 31, 2023
Common Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001
Common Stock, Shares Authorized 100,000,000 100,000,000
Common Stock, Shares, Issued 43,516,631 42,887,052
Common Stock, Shares, Outstanding 42,488,445 41,858,866
Preferred Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001
Preferred Stock, Shares Authorized 10,000,000 10,000,000
Preferred Stock, Shares Issued 0 0
Parent Company    
Common Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001
Common Stock, Shares Authorized 100,000,000 100,000,000
Common Stock, Shares, Issued 43,516,631 42,887,052
Common Stock, Shares, Outstanding 42,888,445 41,858,866
Preferred Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001
Preferred Stock, Shares Authorized 10,000,000 10,000,000
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
v3.25.0.1
Schedule 1-Parent Only Disclosures Condensed Statements of Cash Flows (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]      
Stock-based compensation expense $ 33,432,000 $ 33,161,000 $ 33,393,000
Other, net (1,748,000) 1,347,000 1,051,000
Net cash provided by (used in) operating activities 48,287,000 18,638,000 (8,000,000)
Net Cash Provided by (Used in) Investing Activities [Abstract]      
Cash paid in business acquisition, net of cash acquired 0 0 (15,034,000)
Purchases of property, equipment, and internal-use software (9,716,000) (18,280,000) (17,088,000)
Other 2,099,000 1,585,000 (1,598,000)
Net cash provided by (used in) investing activities (13,457,000) 7,639,000 (67,516,000)
Dividends from subsidiaries 12,800,000 14,900,000 6,900,000
Net Cash Provided by (Used in) Financing Activities [Abstract]      
Payments for Repurchase of Common Stock 0 0 (5,755,000)
Proceeds from exercise of stock options 752,000 2,655,000 2,290,000
Shares withheld to satisfy tax withholding (2,519,000) (1,536,000) (4,359,000)
Repayment of debt financing (1,350,000) (1,717,000) (571,000)
Net cash provided by (used in) financing activities (3,957,000) 59,126,000 60,743,000
Net change in cash, cash equivalents, and restricted cash 28,996,000 85,827,000 (16,232,000)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance 170,464,000 84,637,000 100,869,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance 199,530,000 170,464,000 84,637,000
Parent Company      
Net Cash Provided by (Used in) Operating Activities [Abstract]      
Net loss (9,633,000) (44,693,000) (44,672,000)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]      
Loss attributable to investments in subsidiaries (8,707,000) (39,184,000) (19,331,000)
Depreciation and amortization 941,000 494,000 289,000
Stock-based compensation expense 6,178,000 4,575,000 33,393,000
Other, net (395,000) 4,200,000 533,000
Changes in operating assets and liabilities 507,000 6,194,000 (166,000)
Net cash provided by (used in) operating activities 19,087,000 24,791,000 15,650,000
Net Cash Provided by (Used in) Investing Activities [Abstract]      
Cash paid in business acquisition, net of cash acquired 0 0 (15,034,000)
Purchases of property, equipment, and internal-use software (1,201,000) (172,000) (516,000)
Advances to and investments in subsidiaries (13,526,000) (87,198,000) (71,671,000)
Other 2,157,000 1,586,000 (1,598,000)
Net cash provided by (used in) investing activities (12,570,000) (85,784,000) (88,819,000)
Dividends from subsidiaries 12,782,000 14,837,000 6,942,000
Net Cash Provided by (Used in) Financing Activities [Abstract]      
Payments for Repurchase of Common Stock 0 0 5,755,000
Proceeds from exercise of stock options 752,000 2,655,000 2,290,000
Shares withheld to satisfy tax withholding (2,519,000) (1,536,000) (4,359,000)
Proceeds from debt financing, net of financing fees 0 59,972,000 69,138,000
Repayment of debt financing (1,350,000) (1,225,000) (487,000)
Net cash provided by (used in) financing activities (3,117,000) 59,866,000 60,827,000
Net change in cash, cash equivalents, and restricted cash 3,400,000 (1,127,000) (12,342,000)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance 33,957,000 35,084,000 47,426,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance 37,357,000 33,957,000 $ 35,084,000
Subsidiary Issuer      
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]      
Stock-based compensation expense $ 27,300,000 $ 28,300,000